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DRE-1/FBXO11, a conserved F box protein, regulates apoptosis in
C. elegans and is mutated in human lymphoma

Michael Chiorazzi, Ph.D.
The Rockefeller University 2011

In the course of metazoan embryonic and post-embryonic development,
more cells are generated than exist in the mature organism, and these cells are
deleted by the process of programmed cell death. In addition, cells can be
pushed toward death when they accumulate genetic errors, are virally-infected or
are otherwise deemed potentially-harmful to the overall organism.
Caenorhabditis elegans has proved to be an excellent model system for
elucidating the genetic underpinnings of cell death, and research has shown that
the core machinery, made up of the egl-1, ced-9, ced-4 and ced-3 genes, is
conserved across metazoans, and their homologues are crucial for such
diseases as cancer, neurodegeneration and autoimmunity. We used the C.
elegans tail-spike cell as a model to uncover dre-1/FBXO11 as a conserved

apoptotic regulator that controls tail-spike cell death and also plays a role in
human lymphoma.
The tail-spike cell is unique among cells fated for programmed cell death
in two ways. First, unlike most dying C. elegans cells, the tail-spike cell lives for
several hours before its demise, and during this time differentiates. In
comparison, most cells die minutes after birth as undifferentiated cells. Second,
while tail-spike cell death requires both the CED-3 caspase and CED-4/Apaf-1
adaptor proteins, the BH3-only protein EGL-1 is dispensable. Thus, other
gene(s) substitute for egl-1's role as a regulator of caspase activation in this cell,
and we set out to identify the relevant gene or genes.
A screen for mutants in which the tail-spike cell survives inappropriately
yielded a mutant, ns39, in which the ced-3 caspase is transcribed as normal, but
fails to become activated. We mapped and cloned this mutant, and found that
dre-1 (daf-12-redundant-1) is required for caspase activation in the tail-spike cell.
Expression of the dre-1 cDNA in the tail-spike cell rescues the dre-1(ns39) defect
in a cell autonomous manner, and expression studies show that dre-1 is
expressed in the tail-spike cell. Partial loss-of-function alleles of dre-1, when
combined with weak loss-of-function alleles of ced-3 and ced-4, a null allele of
egl-1, or a weak gain-of-function allele of ced-9 exhibit a synergistic loss of tailspike cell death. A null allele of ced-9, however, when combined with a strong
loss-of-function dre-1 allele, suppresses the tail-spike cell death phenotype of the
dre-1(ns39). This epistatic relationship shows that dre-1 acts upstream of, or in

parallel to ced-9. These results show that dre-1 has a central role in tail-spike
cell death, and are consistent with it acting in place of egl-1 to promote tail-spike
cell death.
DRE-1 is an F box protein, and we showed via RNAi and genetic
experiments that DRE-1 acts in an SCF complex with CUL-1 and SKR-1 to
regulate tail-spike cell death, and present evidence that DRE-1 and CED-9 bind
to each other in vitro. These results suggest a model in which the dre-1 SCF
complex ubiquitinates CED-9 to eliminate its anti-apoptotic function and open the
way for the cell to die.
A collaboration with Louis Staudt and Lixin Rui at the National Cancer
Institute revealed that dre-1ʼs human homologue, FBXO11 is mutated or deleted
in 5% of germinal center-like diffuse large B cell lymphomas, and that
reintroduction of the gene into lymphoma cell lines that have deleted it induces
apoptosis. In addition, FBXO11 binds to BCL2 in lymphoma cell lines and
induces the degradation of BCL2, and expression of BCL2 rescues the toxicity of
FBXO11.
Taken together, our results establish dre-1/FBXO11 as a regulator of
apoptosis in C. elegans and human lymphoma, and suggest a model in which
DRE-1/FBXO11 ubiquitinates and degrades BCL2, a major anti-apoptotic protein.
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Chapter 1: Introduction

In the development of nearly all metazoans, more cells are generated than
exist in the mature animal, and these cells extra cells are fated to die by the
process known as programmed cell death or apoptosis. While developmental cell
deaths were first observed in the 19th century, the appreciation that these were a
normal facet of producing a multicellular organism did not arrive until
Glucksmanns work in the 1950s (Glucksmann, 1951). His descriptive review set
the stage for future studies on apoptosis.

Genetic control of programmed cell death
A major advance in understanding the genetic basis of this process came
in H. Robert Horvitzs lab in the 1980s and 90s, when the first genetic mutants
were isolated in which cell deaths failed to occur. Sulston and Horvitz (Sulston
and Horvitz, 1977) had recognized that Nomarski differential interference contrast
microscopy could be used to identify dying cells as they become round corpses.
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A screen in a ced-1 engulfment-defective background, in which corpses persist
and are easily identified, yielded the ced-3(n717) mutant, in which nearly all cell
deaths are eliminated, yet no changes occur in the stereotyped cell lineage (Ellis
and Horvitz, 1986). egl-1 had been previously isolated and recognized to involve
deaths of the hermaphrodite-specific neurons (HSNs) that control egg-laying, and

ced-4(n1162) was isolated as a suppressor of egl-1(n1084) (Ellis and Horvitz,
1986). Finally, ced-9 was isolated as a gain-of-function allele in a similar screen
for inappropriate survival, and was shown to act as an anti-apoptotic gene
(Hengartner et al., 1992). These results defined C. elegans as an ideal system
for identifying cell death regulators, established the counting of extra cells in the
anterior pharynx as a technique for assessing cell death, and ordered these
genes into a genetic pathway (Fig. 1).

egl-1
(BH3-only)

ced-9
(BCL2)

ced-4
(Apaf1)

ced-3
(caspase)

Apoptosis

Fig. 1. The core cell death machinery in C. elegans and their vertebrate
homologues.

When the molecular identities of the core apoptotic machinery were
elucidated, the field had its first inklings of what the mechanism of cell death
might be, and that these genes were conserved in sequence and function across
metazoans (Conradt and Horvitz, 1998; Hengartner et al., 1992; Yuan and
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Horvitz, 1992; Yuan et al., 1993). ced-3 was found to encode a cysteine
protease, similar to the vertebrate interleukin-1-converting enzyme (Yuan et al.,
1993). A novel class of proteins was identified with the cloning of ced-4 (Yuan
and Horvitz, 1992), but later was found to be homologous to the mammalian
Apaf-1 gene (Zou et al., 1997). BCL2 had been previously cloned as the gene
translocated to the immunoglobulin locus in human follicular lymphoma, and
shown to prevent cell death in B cells and T cells (Tsujimoto et al., 1984; Vaux et
al., 1988). Thus, the connection to BCL2 was immediately made when ced-9, its
homologue, was identified (Hengartner et al., 1992) and further when the
molecular nature of ced-9(n1950) was elucidated (Hengartner and Horvitz, 1994).
Finally, when egl-1 was identified and shown to be a pro-apoptotic gene
containing a BCL2-homology-3 (BH3) domain, it fit well with the cloning in the
preceding years of several mammalian cell death activators with BH3 domains:
Bid, Bad, Bax and Bak. Thus, the C. elegans core apoptotic machinery was
identified and models for its function were proposed and later validated.
The current model for activation of programmed cell death in C. elegans
(Fig. 2) begins with a cell not yet fated to die, in which CED-9 protein is tethered
to the mitochondrial outer membrane, and a CED-4 dimer is being held inactive
by CED-9. This complex prevents CED-4 from binding to inactive CED-3, which
is cytosolic and most-likely inherited (Maurer et al., 2007). Thus the cell has the
potential to undergo apoptosis, but remains alive until an initiating stimulus
induces its death (Shaham and Horvitz, 1996a). When EGL-1 is expressed, it

3

binds to CED-9, inducing a conformational change that results in the release of
CED-4. Now free from CED-9 inhibition, CED-4 forms a higher order structure,
the “apoptosome” which binds to cytosolic CED-3, bringing the protease into
position to be cleaved and become active. Active CED-3 further cleaves CED-3
zymogens and soon, through a feed forward mechanism, all CED-3 becomes
active. The active protease cleaves cellular proteins after aspartate residues,
rapidly dismantling the cell.

4

Fig. 2. The current model for the apoptotic pathway in C. elegans.
In most or all cells, inactive CED-3 zymogen is available in the cytosol, while
CED-9 is tethered to the mitochondrial membrane and holds CED-4 inactive.
Once the apoptotic pathway is engaged, egl-1 is transcribed. The EGL-1 protein
binds to CED-9, releasing CED-4, which forms an oligomer. This complex
associates with CED-3, leading to its proteolytic cleavage and activation. Active
CED-3 dismantles the cell.

5

The tail-spike cell as a model for investigating programmed cell death
John Sulston, in his landmark paper, The Embryonic Cell Lineage of the

Nematode Caenorhabditis elegans, described his observations regarding cell
death:
“In the course of the lineage, one in six of all cells produced subsequently
dies; their identity and the approximate times of their deaths are predictable. The
mode of death is similar to that seen previously in the postembryonic lineages. In
some cases death occurs several hours after birth, so that it is possible for the
cells to function in some manner before being discarded. A good example is the
pair of tail spike cells, which fuse together, form a slender bundle of filaments in
the tip of the tail, and then die. At the other extreme are the majority of
programmed deaths, which occur 20 to 30 min after birth; these cells are born
with very little cytoplasm, and die without differentiating in any obvious way
(Sulston et al., 1983).”
Sulstons short paragraph forms the foundation for this thesis project.
Because screens for global cell death regulators have already been carried out,
we chose to study the death of an individual cell, with the hope of uncovering
novel regulators of apoptosis. But which one to choose? The tail-spike cell was
an inviting model for the reasons suggested by Sulston. First, the cell appears to
have a function before its death – to pattern its sister cell, hyp10, by extending a
process into the tail spike around which hyp10 is wrapped. Second, the tail-spike
cell is unique in its morphology as well as in the timing of its death. Most cell
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deaths occur in small, undifferentiated cells with very little cytoplasm, and death
occurs almost immediately after the birth of the cell. These small cells are most
likely produced by asymmetric cell division and have no function in the animal.
The tail-spike cell, on the other hand, lives about 10 times as long and is thus
similar to cells that die in mammals and other organisms, where the majority of
deaths occur in differentiated cells that receive a signal to die. Thus, what we
learn about tail-spike cell death may be more relevant to cell death biology
outside C. elegans; many developmental deaths in vertebrates occur in cells that
have lived for a long period of time and differentiated fully (Meier et al., 2000).
Following Sulstons description above, electron micrographs confirmed the
anatomy of hyp10 and the tail-spike cell, but the tail-spike cell was not studied
until recently, when Carine Maurer undertook its study as a model for
understanding cell death. The first step in understanding tail-spike cell death was
to develop a specific fluorescent marker for the cell so that its status as alive or
dead could be readily assessed. While a 1.5 kb promoter fragment from the ced-

3 gene drove GFP expression in the cell, it also led to inappropriate survival in
many animals, presumably by preventing endogenous ced-3 transcription in the
cell. Using a 690 bp fragment of the C. briggsae ced-3 gene retained the GFP
expression but also eliminated the cell death defect. This transgene was
integrated and carries the name nsIs25. It was used in all remaining tail-spike
cell studies.
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With a simple assay for tail-spike cell death, i.e., presence or absence of
the GFP-labeled cell, genetic mutants could be used to determine which genes
are required for tail-spike cell death. Like most cell deaths in the worm, ced-3
and ced-4 were required for this cell to die; 100% of animals harboring null
mutations in ced-3 or ced-4 had inappropriately surviving tail-spike cells. While
this result was unsurprising, that egl-1 is not required was unexpected. In egl-1
null animals, 30% of animals had a surviving tail-spike cell, compared to a
complete block in pharyngeal cell death. This result points out that the tail-spike
cell is an interesting model for another reason beyond Sulstons initial
observations: even in the absence of egl-1 activity, the tail-spike cell is able to
“know” that it is fated for death and to execute that death normally in 70% of
animals. egl-1 is not required for germline cell death (Gumienny et al., 1999), but
does control the vast majority of somatic deaths by inhibiting ced-9. In the tailspike cell, however, other gene(s) must serve egl-1s function as an upstream
control of apoptosis. Maurer et al. also showed that the residual egl-1 activity,
though comparatively minor, fully requires ced-9 for its function; ced-9;egl-1
double mutants had 0% tail-spike cell survival, showing that egl-1 acts through

ced-9 in the tail-spike cell. In addition, the ced-9 gain-of-function allele n1950
has a weak effect on tail-spike cell death (3% survival), suggesting that, again,
the tail-spike cell is unique in its cell death mechanisms (Maurer et al., 2007).
Analysis of the ced-3 promoter identified three regions conserved between

C. elegans and C. briggsae that are required for ced-3pro::gfp expression in the
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tail-spike cell and induction of cell death. A screen for lack of ced-3pro::gfp
expression in the tail-spike cell identified several mutants, including two, ns114
and ns115, that mapped to the homeodomain transcription factor pal-1. In these
mutants, ced-3 transcription was reduced, leading to weaker or no GFP
expression as well as inappropriate survival of the tail-spike cell. Electrophoretic
mobility shift assays showed that pal-1 binds to the ced-3 promoter in two of the
regions required for tail-spike cell ced-3pro::gfp expression, suggesting that pal-1
regulates tail-spike cell death by inducing ced-3 transcription during late
embryogenesis, and providing the downstream cue for the cell to die (Maurer et
al., 2007). Intriguingly, pal-1 is homologous to mouse Cdx2 which has been
shown to be a tumor suppressor in mouse gut (Aoki et al., 2003; Bonhomme et
al., 2003).

The ubiquitin proteasome system and its role in cell death regulation
All biologic processes at their core are chemical reactions, and, as any
high school chemistry student knows, the concentrations of reactants and
products are crucial to determining which reactions will occur and how quickly.
Thus, it is not surprising that much of biological regulation occurs via
perturbations of protein levels. For the purposes of increasing protein amounts, a
vast array of mechanisms have evolved: transcription factors, chromatin
modifications, mRNA trafficking, nuclear receptors and more. Fewer modes exist
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for eliminating proteins, and one system is dominant, perhaps because of the
specificity it imparts: the ubiquitin-proteasome system.
Ubiquitin-mediated protein degradation consists of two steps: first, a target
protein is covalently modified with a chain of ubiquitin molecules; second, the
26S proteasome uses ATP to proteolyze it. In addition to the proteasome and
ubiquitin, E1, E2 and E3 enzymes are required, and these may be single
molecules or multi-subunit complexes. Initially, a ubiquitin monomer is covalently
conjugated to a cysteine residue on one of the few E1s (only one exists in C.

elegans, uba-1). This reaction requires ATP. The ubiquitin is then transferred to
an E2, of which there are more in most genomes; in the human there are about
20 and in the C. elegans genome there are 22 ubc genes. Finally, the ubiquitin is
conjugated to its target protein in a reaction that is catalyzed by the E3, the
substrate-specificity protein. Because of this specificity requirement, a huge
number of E3s have been identified in genomes, including hundreds in humans
(Hicke et al., 2005; Hoeller et al., 2006). Ubiquitins C-terminal glycine is
attached with an isopeptide bond to a lysine on the target molecule, followed by
repeated conjugations until a polyubiquitin chain is produced; at least four
ubiquitin monomers are required for trafficking to the proteasome.
The proteasome is a large, multi-subunit complex made up of a 20S core
and two 19S regulatory subunits. The 20S core contains four stacked rings
made up of seven  subunits in the two outer rings and seven  subunits in the
inner rings (Besche et al., 2009). On the inside surface of the cylinder are six
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proteolytic sites that have chymotrypsin-like, trypsin-like and peptidylglutamyl
peptide hydrolytic activities; these active sites digest the substrates into 7-9
residue peptides (Voges et al., 1999).
Because the proteasome is an efficient means to destroy cellular contents,
its gating must be tightly controlled. The gating mechanism involves the Nterminal tails of the  subunits which extend into the central pore and block its
opening until the 19S regulatory particle induces their opening (Groll et al., 2000).
This ungating requires ATP hydrolysis through the six ATPase subunits of the
19S particle. In addition, ATP is required for unfolding of the target protein and
for its entry into the core (Smith et al., 2005). The 19S regulatory subunit binds
to the polyubiquitin chain, and this transduces opening of the 20S gate (BechOtschir et al., 2009; Li and Demartino, 2009). The binding of polyubiquitin to the
Usp14/Ubp6 subunit of the 19S particle appears crucial, as this triggers gate
opening, leading to translocation of the target protein into the core and
subsequent proteolysis (Peth et al., 2009). Further work, especially a high
resolution structure of the 19S particle, is necessary for complete understanding
of this complex machine.
Proteolysis can only be an effective form of regulation if there is specificity
about which proteins are degraded at which times. The specificity in the
ubiquitin-proteasome system comes from E3 ligases, of which there are two
major types in eukaryotes: HECT domain-containing and RING domaincontaining. HECT (homologous to E6-AP C-terminus) domain E3s possess
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catalytic activity in that the ubiquitin moiety is covalently attached to the E3 from
the E2, and this monomer is then passed to the substrate. The HECT domain is
the site of interaction with the E2 and consists of ~350 amino acids, including the
cysteine which receives the ubiquitin monomer (Scheffner and Staub, 2007). 28
HECT domain-containing genes occur in the human genome, including E6-AP
(human papilloma virus E6-associated protein), Nedd4, and the TGF/BMP
regulators Smurf1 and Smurf2.
The majority of E3s are of the RING (really interesting new gene) domain
type, with at least 300 occurring in the human genome (Deshaies and Joazeiro,
2009). The RING domain is made up of cysteines and histidines spaced with
other amino acids in an orientation that coordinates two zinc ions within the
protein, and it is through this domain that E2s are recruited. Among RING E3s,
two classes exist: those in which the RING domain and substrate-binding domain
are in the same protein, and those in which a generic RING domain protein
serves as a subunit in a complex with other proteins, including a substratebinding protein. Of the latter type, the most common are SCF complexes, in
which an Rbx/Roc protein provides the RING domain for E2 binding, a cullin
protein serves as a scaffold to bind the RING domain protein and a SKP1-related
protein. The substrate specificity in the SCF complex comes from the F box
protein, which binds to SKP1 via its F box domain and the substrate through its
substrate specificity site, bringing the substrate in proximity with the E2 and
catalyzing ubiquitin conjugation.
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The F box is named for cyclin F, the first protein recognized with this
domain (Kraus et al., 1994), but the first SCF complex described consists of

Saccharomyces cerevisiae Cdc4 as the F box protein along with Cul1 and Skp1,
an E3 complex that degrades Sic1 and other proteins (Feldman et al., 1997).
The interaction between Cdc4 and Sic1 requires phosphorylation of Sic1,
underlining a common theme among F box-substrate interactions in which the
substrate must be somehow modified to improve the protein-protein interaction
(Hao et al., 2007). In another example, N-glycan modification is required to
induce interaction of the SCFFbx2 ubiquitin ligase complex with its substrates in the
ER-associated degradation (ERAD) pathway (Yoshida et al., 2002).
Despite the inordinately large number of F box proteins in the C. elegans
genome (at least 200), few have been assigned functions or SCF partners. One
complicating factor is that, instead of one human SKP1, there are 21 C. elegans

skr- (SKP1-related-) genes. Of these, skr-1 and -2 are most closely related to
human SKP1, as well as being adjacent in the C. elegans genome and 83%
identical (Nayak et al., 2002; Yamanaka et al., 2002). Injection of RNAi against

skr-1 or -2 into the gonad of hermaphrodites led to the embryonic lethality of their
progeny, due to cellular hyperplasia, a phenotype similar to cul-1 and lin-23
mutants. Because of the similarity between skr-1 and -2, it is unlikely that the
RNAi is specific to either gene, making it impossible to determine which gene, or
both, is responsible for this phenotype. However, several lines of evidence
suggest that skr-1 alone is relevant. First, Yamanaka et al. report that skr-1 is

13

expressed ubiquitously from gastrulation to adulthood, while skr-2 is restricted to
the gut (Yamanaka et al., 2002). Second, Killian et al. report isolation of a
deletion allele, tm2391, which deletes skr-1 but not skr-2 (Killian et al., 2008).
This allele is embryonic lethal, with rare escapers displaying the SCFlin-23
hyperplasia phenotype. Finally, a hypomorphic missense allele of skr-1, sm151,
fails to complement tm2391, giving further credence to the idea that tm2391
affects only skr-1 (Killian et al., 2008).
While the ubiquitin-proteasome system has a role in virtually every
process in cell biology, it is especially important for the regulation of apoptosis.
The IAP (inhibitor of apoptosis) proteins, for example, are E3 ligases which are
crucial for cell death control in vertebrates and Drosophila. IAPs contain between
one and three BIR (baculovirus IAP repeat) domains which are required for
binding to caspases, as well as a C-terminal RING domain, through which IAPs
mediate E2 recruitment. The Drosophila protein DIAP1 acts as an inhibitor for
caspases to keep them in check; DIAP1 mutants die during embryogenesis due
to excessive cell death (Goyal et al., 2000; Lisi et al., 2000; Wang et al., 1999;
Wilson et al., 2002). In addition to BIR and RING domains, DIAP1 contains an
IAP binding motif (IBM) which mediates its interaction with upstream IAP
antagonists such as Reaper, Hid and Grim. These pro-apoptotic molecules
promote DIAP1 auto-ubiquitination and destruction by the proteasome with the
help of UBCD1, inducing apoptosis (Ryoo et al., 2002; Wilson et al., 2002).
DIAP1 is also controlled by N-end rule ubiquitination, but the physiologic role of
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this modification remains an open question, as it has been reported to be both
pro-apoptotic (Yokokura et al., 2004) and anti-apoptotic (Ditzel et al., 2003).
These results suggest that a pro-apoptotic protein like Reaper binds to
DIAP1 to induce its auto-ubiquitination and degradation, releasing caspases from
BIR domain binding and causing apoptosis. However, deletion of the RING
domain increases rather than decreases apoptosis suggesting that DIAP1 also
contains anti-apoptotic function. DIAP1 polyubiquitinates the caspases DRONC
and drICE, inhibiting their activation either through a non-degradative pathway
(Chai et al., 2003; Ditzel et al., 2008; Lisi et al., 2000; Ryoo et al., 2002; Ryoo et
al., 2004; Wilson et al., 2002). When DRONC is associated with Dark in the
context of the apoptosome, however, DIAP1 appears to ubiquitinate it and induce
its degradation (Shapiro et al., 2008). Thus, the DIAP1 ubiquitin ligase is a
complicated and central regulator of Drosophila apoptosis.
In mammals, the E3 ligase XIAP prevents apoptosis when overexpressed
and inhibits caspases-3, -7 and -9. While the RING domain is not required for
this inhibition in vitro (Deveraux et al., 1997), in vivo deletion of the RING results
in mice predisposed to cancer and susceptible to pro-apoptotic insults (Schile et
al., 2008). This inhibition is the result of polyubiquitination of caspase-3 without
accompanied degradation, suggesting that XIAP acts as an E3 for its function,
not a simple caspase-binding inhibitor. Another mammalian ubiquitin ligase
complex implicated in apoptotic regulation is Bruce/Apollon, an E3 for caspase-9
and Smac/Diablo (Bartke et al., 2004; Hao et al., 2004).
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Ubiquitin modification is not only important for caspase control in
apoptosis, but also in regulating caspase activation in non-death related contexts.
One example is in the process of Drosophila sperm individualization, in which
spermatids remove the bulk of their cytoplasm and organelles in a process that
requires caspases but does not kill the cells (Arama et al., 2003). By screening
through a collection of male-sterile genetic mutants for defects in active caspase
staining, a cullin3-based E3 ligase complex made up of Cul3Testis, Roc1b, and
Klhl10 are required for caspase activation and sperm individualization. dBruce, a
giant BIR and UBC domain-containing protein that is also required for sperm
viability, interacts with the substrate-specificity domain of Klhl10 and may be the
relevant target for this E3 ligase (Arama et al., 2007). The same screen yielded
another mutant, ms771, which maps to a gene containing an F box, nutcracker.
Nutcracker functions in an SCF complex with Cullin-1 and SkpA to regulate
caspase activation in a unique way: it regulates the activity of proteasomes in the
developing spermatid. While there is no change in proteasome number in the
nutcracker mutant, protein extracts from nutracker mutant testes showed a
reduced ability to degrade a fluorogenic probe, suggesting a role for nutcracker in
stimulating proteasome function (Bader et al., 2010).
In addition to direct regulation of apoptosis via caspases, the ubiquitinproteasome system has also been implicated in control of BCL2-family members.
For example, Bim was reported to be ubiquitinated and degraded following
ERK1/2 phosphorylation (Akiyama et al., 2003; Ley et al., 2003). The Bid protein
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must be cleaved to become active, as its N-terminal fragment obscures the proapoptotic BH3 domain, located in the C-terminal fragment. After cleavage, the Nterminal inhibitory fragment is ubiquitinated and degraded, and this ubiquitination
is unusual in that it occurs not on lysines but on serines, cysteines and
threonines (Tait et al., 2007). Zhong et al. reported that a HECT E3 ligase,
HUWE, can bind to and polyubiquitinate MCL-1, an anti-apoptotic BCL2-like
protein, and that HUWE contains a domain similar to the BH3 domain which
promotes binding to MCL-1 (Zhong et al., 2005). Finally, BCL2 has been
reported to be degraded by the proteasome, as well as phosphorylated to
regulate its activity. Dimmeler et al. showed that human endothelial cells treated
with TNF- degrade endogenous BCL2, and that this degradation can be
inhibited by mutating lysines in the protein. In this system, dephosphorylation
increased BCL2 degradation, possibly through a MAP kinase module
(Breitschopf et al., 2000; Dimmeler et al., 1999). Phosphorylation of BCL2 was
also reported to induce its proteasomal degradation, as is commonly the case
with F box protein substrates. The relevant E3 has not been identified, but Lin et
al. reported that the phosphatase PP2A dephosphorylates BCL2 to prevent its
degradation and that reduction of PP2A activity led to BCL2 phosphorylation and
degradation (Lin et al., 2006).
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DRE-1, a conserved F box protein
The mammalian homolog of dre-1, FBXO11, was first named VIT1, as its
partial cDNA was isolated from melanocytes from patients with vitiligo (Le Poole
et al., 2001). In these cells, FBXO11 was expressed at lower levels than in
control melanocytes. An in silico approach was used to identify a putative protein
arginine methyltransferase (PRMT) domain in the protein, although this domain is
divergent from other PRMT proteins (Cook et al., 2006). An in vitro methylation
assay using immunoprecipitated PRMT9 isoform 4 (which lacks the F box) from
HeLa cells, showed the capacity to methylate various histone and synthetic
peptide substrates. Abida et al. reported that FBXO11 can interact with p53 and
induce its neddylation, and that this modification inhibits p53 transcriptional
activity (Abida et al., 2007).
In developing mice, Fbxo11 protein was detected by
immunohistochemistry starting at embryonic day 9.5, when staining was confined
to the developing heart. Later in development, expression was detected in liver,
muscle, palatal epithelia, lung, kidney, adrenal gland, bone marrow, skin,
hematopoietic cells, osteoblasts, spleen and middle ear. In adults, of the tissues
studied, staining occurred in alveolar macrophages, glomeruli and collecting
tubules in the kidney, midbrain, heart and muscle (Hardisty-Hughes et al., 2006).
Two mutant mouse lines exist with lesions in mouse Fbxo11. The Jeff
mouse was isolated from an ENU screen for deafness and exhibits worsening
deafness over time as a heterozygote, possibly due to chronic otitis media
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(Hardisty et al., 2003). Heterozygotes are 21% smaller than their wild-type
littermates and have a mild craniofacial abnormality. As homozygotes, all Jf/Jf
animals died at birth or within a few hours because of respiratory difficulty and
had upper eyelids open. In addition, the craniofacial abnormalities were more
severe, with facial clefting and clefting of the soft or hard palate. A second
mouse, Mutt, also contains a mutation in Fbxo11, and partially recapitulates the
Jeff deafness, craniofacial abnormality and perinatal lethality phenotypes, but
lacks otitis media and is likely a milder hypomorphic allele (Hardisty-Hughes et
al., 2006).
Further studies by the same group focused on TGF- pathway proteins in
the Jeff mouse because the palatal and eyes-open-at-birth (EOB) phenotypes
have been observed in mutants in this pathway such as TGF--3, though not all
mutants with these phenotypes are TGF--related (for example, Apaf-1 null mice
have similar craniofacial and palatal fusion defects). Tateossian et al. showed no
effect of Fbxo11 mutation on expression of Fbxo11, TGF--3, TGF-RI or Smad
4, but an increase in nuclear phospho-Smad2 in developing palates of Fbxo11
homozygotes at E15.5 as assayed by immunohistochemistry, compared to wildtype. While there were no differences in proliferation as measured by Ki67
staining in wild-type vs. Jeff palates, there was a modest but statistically
significant reduction in the number of cells stained with an anti-cleaved caspase3 antibody (Tateossian et al., 2009).
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Characterization of the eyelid phenotype of Fbxo11 homozygotes showed
a similar pattern of staining: no differences were observed in expression of
Fbxo11, TGF--3, TGF-RI or Smad 4, but an increase in nuclear phosphoSmad2 was seen at day 15.5. Again, no differences were evident in Ki67
staining, but there was a significant reduction in the level of cleaved caspase-3 in
Fbxo11 homozygotes. Smad2/+; Fbxo11/+ animals showed a significant lethality
defect (66% died soon after birth), as well as respiratory difficulty.
Immunoprecipitation of Fbxo11 failed to detect an interaction with Smad2 or p53
(Tateossian et al., 2009).
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Chapter 2: Genetic control of tail-spike cell fusion and tail
morphogenesis

2.1 Background
As reported by Sulston, the tail-spike cell is born as two precursor cells, the
sisters of the hyp10 precursors, which fuse during embryogenesis to form a
single syncitium, differentiate by extending a thin microtubule-containing process
posteriorly, and die during late embryogenesis (Fig. 3).

Fig. 3. The life and death of the tail-spike cell.
The tail-spike cell lives for ~340 minutes, and during that time undergoes fusion
and differentiation. Reproduced from (Maurer et al., 2007).
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In C. elegans, 300 out of 959 nuclei of the somatic cells are parts of
syncitia. In addition, because of the stereotyped nature of C. elegans
development, the cells which fuse have the same partners and fuse predictably.
Two genes have been isolated from screens for defective fusion, eff-1 and aff-1,
which are conserved in other nematodes but do not have homologues in other
organisms. eff-1 was isolated from a screen in which animals expressing an
adherens junction protein labeled with GFP (AJM-1::GFP) failed to fuse cells that
normally fuse. eff-1 mutants fail to fuse all 43 epidermal cells that are
programmed to fuse during embryogenesis, and also show defects in fusions
post-embryonically (Mohler et al., 2002). Mohler et al. reported that eff-1 mutants
have abnormalities in tail-spike morphogenesis, as well as misshapen male tails
in which the tail-spike persists inappropriately. It was later shown that eff-1 is
required in both fusing cells to induce fusion, and that expression of eff-1 was
sufficient to induce fusion of heterologous insect cells (Podbilewicz et al., 2006).
While the majority of fusions require eff-1, certain cells remain competent
to fuse in eff-1 mutants, including the anchor cell, which fuses during normal
vulval development to open the vulva for egg-laying. Sapir et al. screened for
egg-laying defective animals and examined anchor cell fusion to identify a
mutation in the aff-1 gene (anchor cell fusion failure-1) (Sapir et al., 2007). aff-1
is structurally similar to eff-1, and, like eff-1, can induce fusion when expressed
ectopically in C. elegans as well as when expressed in heterologous cells.
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While the work described above defined the genes necessary for many
fusions in C. elegans development, the gene(s) required for tail-spike cell fusion
were not known. In addition, the role of fusion in regulation of cell death has not
been investigated.

2.2 Results

aff-1 is required for tail-spike cell fusion
We wondered whether fusion played a role in tail-spike cell death. To
address this question, we first tested whether aff-1 (anchor cell fusion failure-1), a
newly-described fusogen that is required for fusion of the anchor cell during
vulval development as well as for the fusions of a number of other cell pairs, was
required for tail-spike cell fusion. A previously-isolated fusogen, eff-1 (epithelial

fusion failure-1) was found by Carine Maurer to have no role in tail-spike cell
fusion (Maurer, PhD thesis). aff-1, however, was required for tail-spike cell
fusion, as we observed two healthy but unfused cells in aff(tm2214);ced-

3(n717);nsIs25 animals. We conclude that aff-1, but not eff-1, is required for tailspike cell fusion.
For further evidence that aff-1 is involved in tail-spike cell fusion, we tested
whether a transcriptional reporter for aff-1 was expressed in the tail-spike cell.
Indeed, the 4.5 kb genomic fragment upstream of the aff-1 start codon drove
GFP expression within the tail-spike cell in ced-3(n717) animals (Fig. 4). GFP
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was also expressed in other cells throughout the animal, but, importantly, not in
hyp10.

Fig. 4. aff-1pro::gfp is expressed in the tail-spike cell.
Fluorescence images of tails of two representative L1 ced-3(n717) animals in
which GFP expression is evident in the tail-spike cell.

Having established aff-1 as the relevant fusogen for the tail-spike cell, we
could address whether fusion was required for death. In aff-1(tm2214);nsIs25
animals, 0% of L1s had surviving tail-spike cells, showing that unfused cells are
fully capable of undergoing programmed cell death.

24

Tail-spike cell non-fusion affects tail morphogenesis
While examining aff-1(tm2214) mutants, we noticed an unusual tail
morphology defect: a large number of L1s had forked tails. Quantification of this
serendipitous finding showed that 78% of aff-1(tm2214) L1s had forked tails,
while 0% of N2 L1s and 0% of eff-1(hy40) L1s had forked tails (eff-1 animals
frequently had rounded tail tips or tail tips with knobs attached) (Fig. 5). The
percentage of animals with forked tails in aff-1(tm2214) may be an underestimate
because we observed some animals in which one fork was significantly smaller
or broken, suggesting that the fork may not always be even and the smaller half
may be lost during the animals life.
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Fig. 5. aff-1(tm2214) but not eff-1(hy40) or wild-type animals have forked
tail-tips.
Top: Quantification of the percentage of animals with forked tails, as assessed by
DIC microscopy (n>100 for each genotype).
Bottom: Representative images from two L1 aff-1(tm2214) animals, showing the
forked tail defect common in this mutant.
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Given that Sulston had postulated that the tail-spike cell process forms a
scaffold for hyp10 morphogenesis, and given the electron microscopic (EM)
results showing a microtubule core within the tail-spike cell that persists after its
death, we wondered whether the aff-1(tm2214) forked tail phenotype might be
related to the tail-spike cells remaining unfused. In examining aff-1(tm2214);ced-

3(n717);nsIs25 animals more carefully, we were able to identify many animals in
which each unfused tail-spike cell had generated a process extending into the
posterior of the animal. Thus, it is likely that, with two microtubule-containing
processes within itself instead of one, hyp10 is improperly patterned in aff-

1(tm2214) animals, and the forked tail phenotype results. While these results are
not proof that the tail-spike cell fusion defect is responsible for the forked tail
phenotype (a tail-spike cell-specific rescue of the aff-1 mutation would be
necessary to prove this, an experiment that is rendered impossible because we
lack an early tail-spike cell-specific promoter), the correlation between two
processes and forked tails is striking evidence to support this idea.

2.3 Conclusion
These results lend support to the Sulston model in which the tail-spike
cells major, or possibly sole, function is to extend a microtubule-laden process
posteriorly during embryogenesis to direct proper hyp10 morphogenesis and tailtip shape. Presumably, when this function has been served, the cell is no longer
necessary for the organism, and thus undergoes programmed cell death. In the
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context of failed tail-spike cell fusion as in aff-1 mutants, each unfused tail-spike
cell appears able to direct morphogenesis of a separate tail-spike, leading to a
forked tail. Thus, proper tail-spike cell morphogenesis in the form of a fused cell
with one process is crucial to building the elegant C. elegans tail-spike.
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Chapter 3: Cloning and characterization of a novel regulator of
programmed cell death

3.1 Background
The tail-spike cell as a system for uncovering apoptotic regulators
A great many screens have been performed to find regulators of
apoptosis, and these screens have defined the core apoptotic machinery to
include egl-1, ced-9, ced-4 and ced-3 in a linear pathway.

egl-1
(BH3-only)

ced-9
(BCL2)

ced-4
(Apaf1)

ced-3
(caspase)

Apoptosis

With these screens for global cell death genes saturated, we turned to studying
individual cells as a way to better understand the mechanisms of apoptosis. Of
the individual cells that undergo programmed cell death in C. elegans, we chose
to study the tail-spike cell for two major reasons. First, the tail-spike cell is one of
only a few cells that is long-lived during C. elegans development before
undergoing apoptosis. While most cells die within 20 minutes of being born, the
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tail-spike cell lives 10 times as long, and during that time differentiates by
extending a process posteriorly. Thus, it more closely resembles the deaths of
mammalian cells, which die after differentiation. Second, and most importantly,
the genetic control of tail-spike cell death is unique. While egl-1 is required for
virtually all other deaths in the worm, in the tail-spike cell it is dispensable for
death. Worms carrying a non-functional egl-1 gene have a persistent tail-spike
cell 30% of the time. In other words, in 70% of animals, the tail-spike cell can be
specified for death and execute that fate in the complete absence of egl-1 activity
(Fig. 6). With ced-3 and ced-4 being completely required for tail-spike cell death,
we recognized that the tail-spike cell represents an ideal system for uncovering
new regulators of caspase activation: in the absence of egl-1, some other
gene(s) must be responsible for activating ced-3 and ced-4. We set out to
identify these gene(s).
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Fig. 6. Tail-spike cell death requires ced-3 and ced-4 but egl-1 is
dispensable for death.
Percentage of animals with a surviving tail-spike cell in ced-3(n717), ced4(n1162) and egl-1(n1084n3082) strains. All strains contain the nsIs25
transgene to mark the tail-spike cell (n>100 for each). Reproduced from (Maurer
et al., 2007).
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3.2 Results

A forward genetic screen for regulators of tail-spike cell death
To identify the gene(s) acting in place of egl-1 in the tail-spike cell to
regulate apoptosis, Carine Maurer performed a forward genetic screen on
animals carrying the ced-3pro::gfp integrated transgene (nsIs25) which marks the
tail-spike cell. She mutagenized nsIs25 animals with ethyl methanesulfonate,
screened the F2 progeny for animals with surviving tail-spike cells and isolated 8
putative mutants, ns16, ns17, ns18, ns19, ns38, ns39, ns40 and ns41. In
addition to looking for animals in which the tail-spike cell survived, she focused
on mutants that lacked a global cell death defect as a way to avoid alleles of ced-

3 and ced-4. We checked these 8 mutants for survival of the tail-spike cell: 5/8
had <1% tail-spike cell survival, and because of the low penetrance of the defect,
chose not to pursue these mutants (Fig. 7). Of the remaining 3, ns38 had a
significant global cell death defect (7.2 extra cells in the pharynx, as assayed by
Shai Shaham), and ced-3 failed to complement this defect. We conclude that

ns38 is an allele of ced-3. The remaining two mutants, ns39 and ns40, fail to
complement each other, and thus likely represent lesions in distinct genes. 19%
of ns40;nsIs25 animals have a surviving tail-spike cell.

32

Fig. 7. Tail-spike survival in mutants isolated from a forward genetic
screen.
Percentage of animals with a surviving tail-spike cell in strains with the indicated
genotypes. ns16, ns17, ns18 and ns19 contain the nsIs23 transgene while ns38,
ns39, ns40 and ns41 contain the nsIs25 transgene to mark the tail-spike cell
(n>100 for each).
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The tail-spike cell survives inappropriately in ~79% of animals carrying the

ns39 mutation, compared to 0% in wild-type animals. In addition, the surviving
tail-spike cell in ns39;nsIs25 animals expresses ced-3pro::gfp, indicating that

ced-3 transcription is intact and placing ns39 in a different class from pal-1-like
mutants in which tail-spike cell death is prevented by lack of ced-3 transcription.
In ns39 mutants the tail-spike precursor cells fuse properly and the cell extends a
process posteriorly, making the surviving tail-spike cells in this strain
indistinguishable from those in ced-3 or ced-4 mutant strains.
The result that the tail-spike cell survives inappropriately in 79% of animals
implies that it is born and dies appropriately in the remaining animals. To test
this assumption, I crossed the ns39 mutation to the ced-5(n1812) background, in
which apoptotic corpses are not engulfed, making their identification by DIC
microscopy easy. In this background, the tail-spike cell survived 71% of the time
and in all of these animals no corpse was evident in the tail (Fig. 8). In 29% of
animals, a corpse was present in the proper position that harbored residual GFP
expression, and no other cells in the area expressed GFP. Finally, there were
zero animals in which neither a surviving cell nor a corpse were present, or both
were present. Thus, the reason for no tail-spike cell being evident in ns39;nsIs25
animals is that it has died, not that it was never generated, or that it was alive but
the ced-3pro::gfp marker had not been activated.
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Fig. 8. The ns39 mutation blocks tail-spike cell death but does not alter
cell fate.
The status in L1 animals of the tail-spike cell was assessed in wild-type, ced5(n1812) engulfment defective, and ns39; ced-5(n1812) backgrounds. In wildtype animals, the cell always dies and the corpse is cleared. In ced-5(n1812)
animals, the cell always dies and the corpse is evident in 96% of animals. In
ns39; ced-5(n1812) animals, the cell survives in 71% of animals and can be seen
as a healthy cell; in the remaining 29% of animals, the cell dies and its corpse
can be identified (n>100 for each).
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Because these observations about the ns39 mutation are consistent with it
blocking ced-3 caspase activation in the tail-spike cell to prevent apoptosis, I
decided to pursue this mutant further.

The ns39 mutation maps to the dre-1 gene
After backcrossing five times, I used standard SNP-mapping techniques to
map the ns39 mutation to a region on Chromosome V between -0.183 and 0.109
MU. Within this region, several genes were reported to have an egg-laying
defect, as was observed in the ns39 strain. Of these, I sequenced the dre-1 (daf-

12-redundant-1) gene and identified a C to T change, consistent with this being
an EMS-induced mutation. This lesion is predicted to induce a serine to leucine
missense mutation at position 275 of the protein (based on the “new” cDNA, see
below).

dre-1 was named by Adam Antebis group who were studying the effects
of daf-12 on developmental timing. They isolated several alleles of dre-1,
including dh99 and dh279. I tested whether these alleles shared the tail-spike
cell death phenotype of ns39 by crossing them to the nsIs25 marker. Indeed,
both of these independently isolated alleles showed tail-spike cell death defects,
of 12 and 2%, respectively, consistent with dre-1 being the gene responsible for
the ns39 defect (Fig. 9).
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Fig. 9. Mutations in dre-1 block tail-spike cell death.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). All strains contain the nsIs25 transgene to mark the
tail-spike cell.
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To further demonstrate that dre-1 is the relevant gene for tail-spike cell
death, I did a complementation test between two independently isolate alleles of

dre-1 – ns39 and dh99. 25% of animals with the genotype ns39/dh99 had a
surviving tail-spike cell, showing that ns39 and dh99 fail to complement each
other and lending further support to the idea that dre-1 controls tail-spike cell
death (note that this percentage may be an underestimate of tail-spike cell
survival in these animals as the nsIs25 marker was heterozygous in all animals
scored) (Fig. 10). In the course of this cross, I also generated animals
heterozygous for either ns39 or dh99; none of these animals had a surviving tailspike cell, demonstrating that both mutations are recessive with respect to tailspike cell death. In addition, I found that ns39/gk857 animals (gk857 is a deletion
that removes 599 bp of the dre-1 cDNA from position 155 to 753) are mostly
inviable. The few animals of this genotype I was able to produce died as L1
larvae (5 animals). None of these animals had a surviving tail-spike cell, though
they were very sick and died soon afterwards.
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Fig. 10. dre-1(dh99) and dre-1(ns39) fail to complement each other with
respect to the tail-spike cell death defect.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). All strains contain the nsIs25 transgene to mark the
tail-spike cell.
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If dre-1 is involved in promoting tail-spike cell death, then ectopically
expressing wild-type dre-1 in the tail-spike cell of ns39 mutants should induce
apoptosis. I used several methods to rescue the ns39 phenotype.
First, I injected two overlapping fosmids that include the dre-1 sequence
into the ns39 mutant. WRM067bH07 contains 31.7 kb of genomic sequence,
including 13.5 kb upstream of the “old” dre-1 ATG (see below) and 13.8 kb
downstream of the stop codon. This fosmid rescued the tail-spike cell death
defect fully, giving 2% survival in transgenic animals (Fig. 11). WRM0637aG11
contains 33.7 kb of genomic sequence, including 21.1 kb upstream of the “old”
dre-1 ATG (see below) and 8.2 kb downstream of the stop codon. This fosmid
also rescued the tail-spike cell death defect, giving 7 and 13% survival in two
independent lines. Thus, the information required for rescue is contained within
these ~30 kb of genomic sequence.
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Fig. 11. Two fosmids containing the dre-1 locus rescue the tail-spike cell
death defect in dre-1(ns39) animals.
Percent of animals with a surviving tail-spike cell in wild-type, dre-1(ns39), and
dre-1(ns39) + indicated fosmid (n>100 for each). All strains contain the nsIs25
transgene to mark the tail-spike cell.
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The overlapping region within these two fosmids contains dre-1, acs-1
(fatty acid CoA synthetase-1), F46E10.11 (a predicted non-coding RNA), and

twk-10 (a potassium channel). To determine whether dre-1 is in fact the relevant
gene, I attempted to rescue the ns39 phenotype with the dre-1 cDNA. Initial
attempts to rescue using the cDNA reported by Adam Antebis group (Fielenbach
et al.) driven by 4.4 kb of genomic sequence upstream of the ATG failed to
rescue, and Fielenbach et al. reported difficulty in rescuing with the cDNA and
instead only rescued with a YAC and a 15 kb genomic fragment.
We wondered whether the reported cDNA was incomplete. Examination
of the sequence upstream of the ATG identified a putative splice donor site ~8kb
upstream. In addition, Aceview.org reported an incomplete cDNA clone using
this ATG spliced to the reported sequence that is in frame. To test whether this
putative exon was in fact part of the dre-1 cDNA I performed PCR on cDNA
isolated from mixed stage worms graciously provided by Maya Tevlin. A forward
primer beginning with the “new” ATG and a reverse primer in the “old” first exon
produced a band of the proper size if this “new” exon was in fact spliced to the
“old” cDNA (Fig. 12). Sequencing of this product revealed an in-frame splice
junction. In addition, PCR using a forward primer corresponding to the SL1 splice
leader sequence and a reverse primer within the “new” first exon produced a
product that was the expected length and sequence, showing that this ATG is in
fact utilized in the worm and that it is SL1 spliced. In addition, SL1 splicing
occurs to the “old” dre-1 cDNA, as previously reported (Fielenbach et al.) but it is
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unclear whether this transcript is in fact biologically relevant.

Fig. 12. Exon structure of the “old” versus “new” dre-1 cDNA.
The new cDNA (bottom) includes an exon 8 kb upstream of the originally
reported start codon. SL1 splicing was detected in both forms.

The new cDNA is 258 bp longer, and converts the 5UTR from the old
cDNA into coding sequence, producing a protein that is 86 amino acids longer.
This sequence is conserved in C. briggsae, though it yields no new domains and
is not conserved in other organisms.
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Using this new dre-1 cDNA in rescue experiments proved successful. A
construct consisting of the new dre-1 cDNA under the aff-1 promoter and
including the dre-1 3UTR rescued the dre-1(ns39) tail-spike cell death defect. In
3 independent lines, tail-spike cell survival was reduced from 79% to 11, 22 and
46% (Fig. 13). This experiment warrants two conclusions. First, this shows that
loss of dre-1 is responsible for the ns39 phenotype and establishes dre-1 as a
regulator of apoptosis in the tail-spike cell. Second, because the aff-1 promoter
expresses in the tail-spike cell but not its sister, hyp10, this experiment shows
that dre-1 acts cell autonomously to induce tail-spike cell death.
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Fig. 13. Expression of the DRE-1 cDNA under the aff-1 promoter rescues
the dre-1(ns39) tail-spike cell death defect.
Percent of animals with a surviving tail-spike cell in wild-type, dre-1(ns39), and
dre-1(ns39) + aff-1p::DRE-1 transgenes (n>100 for each). The aff-1 promoter
expresses in the tail-spike cell but not hyp10. All strains contain the nsIs25
transgene to mark the tail-spike cell.
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In addition, we also expressed the dre-1 cDNA under the dpy-30
ubiquitous promoter (Fig. 14). This construct also rescued the dre-1(ns39)
defect, albeit less well, possibly because this promoter is not very strong (Shai
Shaham, personal communication).

Fig. 14. Expression of the DRE-1 cDNA under the dpy-30 ubiquitous
promoter rescues the dre-1(ns39) tail-spike cell death defect.
Percent of animals with a surviving tail-spike cell in wild-type, dre-1(ns39), and
dre-1(ns39) + dpy-30p::DRE-1 transgenes (n>100 for each). All strains contain
the nsIs25 transgene to mark the tail-spike cell.
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Having established that dre-1 is required cell autonomously for tail-spike
cell death, I investigated its expression pattern. Fielenbach et al. had described

dre-1 as being expressed in many cells during embryogenesis, especially
epidermal-like cells (Fielenbach et al., 2007). A 4 kb promoter construct taken
from intron 1 of the dre-1 gene expressed in many cells, including the tail-spike
cell (Fig. 15). The tail-spike cell expression was confirmed by co-expressing RFP
under the control of the ced-3 promoter which marks the tail-spike cell. Thus,

dre-1 is expressed and acts in the tail-spike cell to control death.
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Fig. 15. dre-1 is expressed in the tail-spike cell.
A ~4kb promoter fragment from intron 1 of the dre-1 locus drives GFP expression
in the tail-spike cell. Two representative L1 animals are shown expressing ced3p::NLS-RFP to mark the tail-spike cell, dre-1p::NLS-GFP to mark dre-1expressing cells and the merged image to show their overlap in the binucleate
tail-spike cell. Arrows point of the tail-spike cell. Both animals contain the ced3(n717) mutation to allow visualization of the tail-spike cell in larvae.
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dre-1 interacts genetically with core cell death pathway genes
Our results to this point suggest that dre-1 acts as a pro-apoptotic
molecule in the tail-spike cell to regulate developmental cell death. If this is the
case, we would expect that it would interact genetically with alleles of the core
apoptotic machinery, and the result might be a synergistic increase in tail-spike
cell survival. As an example, combining a weak ced-3 allele (n2436) with the

ced-9(n1950) gain-of-function allele leads to a significant rise in the number of
animals with a surviving tail-spike cell; ced-3(n2436) animals have 59%
inappropriate survival, ced-9(n1950) animals have 3% survival, and ced-

3(n2436);ced-9(n1950) animals exhibit 93% tail-spike cell survival (Fig. 16).
Thus, weakening two parts of the core apoptotic machinery – EGL-1s ability to
inhibit CED-9 and the caspases ability to dismantle the cell – leads to a
synergistic increase in survival. We wondered whether a similar effect would
occur using dre-1 alleles.
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Fig. 16. Combining weak loss-of-function mutations in two apoptotic
regulators leads to a synergistic increase in tail-spike cell survival.
Reproduced from (Maurer et al., 2007).

50

Combining ced-3 and dre-1 alleles does in fact create a synergistic
increase in the cell death defect. For example, while ced-3(n2427);nsIs25
animals have 0% tail-spike cell survival, and dre-1(dh99);nsIs25 animals 12%,

dre-1(dh99);ced-3(n2427);nsIs25 animals have 46% tail-spike cell survival (Fig.
17). Thus, dre-1(lf) mutants are a sensitized background with respect to tailspike cell death, and in the presence of a weakened caspase, the cell survives at
a greatly increased rate.
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Fig. 17. dre-1; ced-3(weak) double mutants display a synergistic increase
in tail-spike cell survival.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). All strains contain the nsIs25 transgene to mark the
tail-spike cell.
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Only one weak ced-4 allele exists, n3158, and a similar analysis showed a
similar synergistic effect (Fig. 18).

Fig. 18. dre-1; ced-4(weak) double mutants display a synergistic increase
in tail-spike cell survival.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). All strains contain the nsIs25 transgene to mark the
tail-spike cell.

53

The ced-9(n1950) gain-of-function allele disrupts EGL-1 binding to CED-9,
creating a constitutive inhibitor of cell death. While this allele has, on its own, a
relatively weak effect on tail-spike cell death, it displays a synergistic increase in
tail-spike cell survival in the absence of full dre-1 activity (Fig. 19).
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Fig. 19. dre-1; ced-9(n1950) double mutants display a synergistic increase
in tail-spike cell survival.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). All strains contain the nsIs25 transgene to mark the
tail-spike cell.
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Carine Maurer showed that egl-1 is dispensable for tail-spike cell death: in

egl-1(null) mutants, the tail-spike cell dies in 70% of animals. This result raises
the question of what is substituting for egl-1 in the tail-spike cell to regulate
caspase activation? Could dre-1 be responsible for this activity? If so, we would
again expect a synergistic effect of combining an egl-1 mutation with dre-1
mutations. This is in fact what we see, as double mutant combinations show
increased tail-spike cell survival (Fig. 20).
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Fig. 20. dre-1; egl-1(null) double mutants display a synergistic increase in
tail-spike cell survival.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). All strains contain the nsIs25 transgene to mark the
tail-spike cell.
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These results showing that dre-1 mutations enhance mutations in proapoptotic genes are consistent with dre-1 acting as a bona fide apoptotic
regulator in the tail-spike cell. We wondered whether ced-9, the major antiapoptotic molecule in C. elegans, would also interact genetically with dre-1.
Constructing strains with the ced-9(n2812) allele is complicated by the fact that

ced-9(n2812) homozygotes are inviable due to excess cell death; thus, a weak
ced-3 allele must always be present in the background to bypass this defect.
Comparing dre-1(ns39);ced-3(n2427) animals to ced-9(n2812);dre-1(ns39);ced-

3(n2427) animals shows a marked decrease in cell survival, with the levels closer
to ced-3(n2427) alone (Fig. 21). This experiment demonstrates an epistatic
relationship between ced-9 and dre-1 with respect to tail-spike cell death: in the
absence of ced-9, dre-1 status is largely irrelevant.
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Fig. 21. dre-1 acts upstream of, or in parallel to, ced-9.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). All strains contain the nsIs25 transgene to mark the
tail-spike cell.
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This result tells us several things. First, it shows that ced-9, despite egl-

1s minor role in tail-spike cell death, retains its anti-death function in this cell.
Before we uncovered dre-1s function in tail-spike cell death, the only role for

ced-9 was evident in egl-1(n1084n3082);ced-9(n2812);ced-3(n2427) animals,
where the cell dies 100% of the time and which shows that egl-1 acts through

ced-9 to promote death, albeit in a minor role. Second, this result shows that
dre-1 acts upstream of, or in parallel to, ced-9 to control tail-spike cell death.
Third, it shows that dre-1 may have a role as a controller of cell death through a
different pathway, as 20% of animals retain a surviving tail-spike cell in this
strain. Thus, even in the absence of ced-9, dre-1 still affects cell death.
The homeodomain transcription factor pal-1 is required for tail-spike cell
death as a transcriptional activator of ced-3 just prior to death (Maurer et al.,
2007), which, given that dre-1 appears to act upstream of or in parallel to ced-9,
would suggest that pal-1 should be epistatic to dre-1. pal-1;dre-1 double mutants
support this prediction, as they show diminished ced-3pro::gfp expression (Fig.
22). These results are consistent with dre-1 acting upstream of or in parallel to

ced-9 and pal-1 activation of ced-3 transcription being far downstream in the
cascade of tail-spike cell death.
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dre-1(dh99)

dre-1(dh99);
pal-1(ns114)

Fig 22. pal-1 is epistatic to dre-1 with respect to ced-3 transcription.
One second exposures of surviving tail-spike cells in dre-1(dh99) and dre1(dh99);pal-1(ns114) animals. Note that GFP expression is significantly dimmer
in the pal-1 mutant, as would be expected if it is acting downstream to regulate
ced-3 transcription. Both animals contain the nsIs25 ced-3pro::gfp transgene to
visualize ced-3 transcription.
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Because of pal-1s effects on ced-3 transcription, pal-1 mutants also
display a tail-spike cell death defect, with 30% of animals showing a surviving
tail-spike cell in pal-1(ns114) animals. Scoring tail-spike cell survival in these
animals is complicated by the fact that the ns114 mutation reduces ced-3pro::gfp
expression in the tail-spike cell, making it difficult to discern whether the tail-spike
cell has survived. The reduced ced-3pro::gfp is incompletely penetrant, however,
making it possible to see the tail-spike cell in some animals, with the caveat that
this is an underestimate of tail-spike cell survival. Despite that limitation, we were
able to see an increase in tail-spike cell survival when combining pal-1 and dre-1
mutants, consistent with both having partial effects on tail-spike cell death (Fig.
23).
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Fig. 23. dre-1; pal-1(ns114) double mutants display an increased tail-spike
cell death defect.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). These numbers are an underestimate because they
do not count animals in which the pal-1 mutation completely abolished ced3pro::gfp transcription in the tail-spike cell, which we are unable to score. All
strains contain the nsIs25 transgene to mark the tail-spike cell.
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dre-1 does not regulate pharyngeal cell death
Having established dre-1 as a regulator of apoptosis in the tail-spike cell,
we wondered whether it plays a similar role in other cells. To address this, we
used the pharynx assay, in which the number of cells present in the anterior
pharynx is counted under DIC microscopy. In animals with mutations in the core
apoptotic machinery, as many as 14 extra cells accumulate in the anterior
pharynx, and this assay allows quantification of the global cell death defect.
These assays were performed by Shai Shaham.
First, we addressed whether dre-1(ns39) animals had extra cells in the
pharynx (Table 1). As we expected from initial experiments by Carine Maurer
described above in which mutants from the screen were secondarily screened by
checking for a global cell death defect, dre-1(ns39) animals had no extra cells in
the pharynx. This result is also unsurprising considering that dre-1 was not
isolated in any screens for global cell death defects based on the pharyngeal cell
death assays.
We looked for other evidence that dre-1 plays a role in pharyngeal cell
death by asking whether the dre-1(ns39) mutation could enhance the death
defect of weak ced-3 alleles: dre-1 might have a supporting role in promoting
death which might only be uncovered in the setting of weakened caspase activity.
However, dre-1(ns39);ced-3(n2436) animals did not show an increased number
of cells in the pharynx suggesting that dre-1 may not play a part in these cell
deaths (Table 1). As a parallel experiment, we tested whether egl-
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1(n1084n3082)/+; dre-1(n39)/+ animals had extra cells in the pharynx, as our tailspike cell data suggest that dre-1 acts upstream of ced-9, in place of egl-1.
Again, no extra cells were found in the pharynxes of these animals, making it
unlikely that dre-1 is a major player in pharyngeal cell death (Table 1). Thus, we
conclude that dre-1 is required for tail-spike cell, but not pharyngeal cell death.

Genotype

# extra cells

ced-3(n2436)

4.2

dre-1(ns39)

0

ced-3(n2436);
dre-1(ns39)

3.7

dre-1(ns39)/+;
egl-1(n1084n3082)/+

0

Table 1. The dre-1(ns39) mutation does not affect cell death in the
pharynx.
Global cell death was assessed in the anterior pharynx in ced-3(n2436), dre1(ns39), ced-3(n2436);dre-1(ns39) double mutants and dre-1(ns39)/+;egl1(n1084n3082)/+ heterozygotes. No effect was seen in dre-1 mutants (counts
performed by Shai Shaham).
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C05C8.6, a BTB/POZ domain protein, may play a minor role in tail-spike cell
death
A high-throughput yeast two-hybrid screen of thousands of C. elegans
proteins showed that DRE-1 interacts with C05C8.6 in this assay (Li et al., 2004).
C05C8.6, a BTB/POZ domain protein, remains uncharacterized, but the fact that
it contains a BTB domain was intriguing to us, considering the role that BTB
domain-containing proteins have in the ubiquitin-proteasome system. In addition,
Li et al. reported that C05C8.6 interacts with itself; GLY-4, a predicted UDPgalNAc-ase; GST-24, a glutathione transferase; RAD-26, a helicase; and
F52B11.1, a PHD Zn-finger protein. Alleles are available for C05C8.6, gly-4 and

gst-24, and we tested whether any of these had an effect on tail-spike cell death.
On their own, mutations in none of C05C8.6, gly-4 or gst-24 blocked tailspike cell death, with 1%, 1% and 1.5% of animals having an inappropriately
surviving tail-spike cell, respectively (Fig. 24). We tested whether these
mutations had any effect on tail-spike cell death in the context of the dre-1(ns39)
mutation. C05C8.6(tm3719) had a slight suppressive effect on tail-spike cell
death in the C05C8.6(tm3719); dre-1(ns39) double mutant: 59% vs. 79%
inappropriate survival (Fig. 24). This suppression could suggest that C05C8.6
acts downstream of, or in parallel to dre-1 to regulate tail-spike cell death, but
such a weak effect is difficult to interpret, and could also be due to other
mutations in the background. gly-4(ok2943) enhanced tail-spike cell survival
slightly when combined with the dre-1(ns39) mutation, increasing survival from
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79% to 87% (Fig. 24). Again, this weak enhancement of tail-spike cell survival is
difficult to interpret, although the fact that dre-1 contains three CASH domains
reported to be involved in carbohydrate binding makes gly-4 an intriguing gene.

gst-24(ok3042) had no significant effect on the dre-1(ns39) mutant, with tail-spike
cell survival of 70% vs. 79%. We conclude that C05C8.6 may play a minor role
in tail-spike cell death, and gly-4 may as well, while gst-24 is unlikely to be
involved in this process.
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Fig. 24. C05C8.6 and its putative interacting partners play a minor or
negligible role in tail-spike cell death.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). All strains contain the nsIs25 transgene to mark the
tail-spike cell.
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Tail-spike cell death is not affected by heterochronic genes but may be
subtly controlled by a microRNA
The dre-1 3UTR contains several putative microRNA binding sites as
predicted by various online tools. mir-2 and mir-71 have high scores for
complementarity and alleles exist for both of these genes. To test whether mir-2
or -71 have a role in tail-spike cell death, we crossed both of these mutants to the
tail-spike cell GFP reporter, nsIs25. Neither mir-2;nsIs25 nor mir-71;nsIs25
animals had any evidence of tail-spike cell survival (Fig. 25). We also tested
whether mir-71 interacted genetically with dre-1 in any way. Surprisingly, mir-

71;dre-1(ns39);nsIs25 animals had an enhanced tail-spike cell death defect,
suggesting that mir-71 may have a weak pro-death effect that is only unmasked
in the context of the dre-1 mutant.
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Fig. 25. A mir-71 mutation enhances the tail-spike cell death defect in dre1(ns39) animals.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). All strains contain the nsIs25 transgene to mark the
tail-spike cell.

70

dre-1 was isolated from a screen for enhancers of a daf-12 mutations
effect on heterochronic phenotypes (distal tip cell migration and seam cell
fusion). The genes lin-4, lin-46, lin-29 and lin-28 have been implicated in these
processes and thus we wondered whether there was a connection between tailspike cell death and any of these genes. Crossing each to the nsIs25 tail-spike
cell marker showed that none of the resulting strains had tail-spike cell death
defects (Fig. 26). With this result, in concert with the fact that all heterochronic
phenotypes are post-embryonic while tail-spike cell death occurs during
embryogenesis, we conclude that dre-1s role in regulating tail-spike cell death is
independent of these heterochronic pathways.
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Fig. 26. dre-1 does not act in a heterochronic pathway to regulate tailspike cell death.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). All strains contain the nsIs25 transgene to mark the
tail-spike cell.

72

3.3 Conclusions
The major draw of studying the tail-spike cell is that, while its death
requires ced-3 caspase activation through ced-4, egl-1 plays a relatively minor
role in controlling ced-3 activation. Thus, the power of C. elegans genetics can
be used to identify novel genes that influence caspase activation, and act in egl-

1s stead.
Several lines of evidence show that dre-1 is a bona fide cell death
regulator in the tail-spike cell, and is in fact a substitute for egl-1. First, mutations
in dre-1 block tail-spike cell death and these mutations can be rescued by cell
autonomous expression of wild-type dre-1. We would expect that, like the core
cell death machinery, dre-1 would act in the cell that it was involved in killing.
Second, the dre-1(ns39) mutation blocks tail-spike cell death in most animals, but
in those animals in which the cell dies, the death appears normal, and a
classically apoptotic corpse is evident by DIC microscopy. Also, in those animals
in which the tail-spike cell survives, it is morphologically indistinguishable from a
surviving tail-spike cell seen in a ced-3, ced-4 or egl-1 mutant. Thus, dre-1(ns39)
does not cause a cell fate change such that the embryonic lineage is altered and
the cell is never born or becomes a drastically altered cell. Third, mutations in

dre-1 synergize with mutations in core cell death components, suggesting that
the dre-1 mutant background is sensitized with respect to tail-spike cell death.
Furthermore, the genetic results show that dre-1 acts upstream of, or in parallel
to ced-9 to regulate tail-spike cell death, and that pal-1 is downstream of dre-1 as
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well. These results do not address how dre-1 controls tail-spike cell death, but
the domain structure of dre-1 hints at a role as an E3 ligase for the ubiquitinproteasome system.
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Chapter 4: DRE-1 acts in an SCF complex to regulate tail-spike
cell death

4.1 Background
The ubiquitin-proteasome system is the major control over protein turnover
in eukaryotic cells, and as such plays a crucial role in all biologic processes. The
ability to precisely affect levels of individual proteins within the cellular
environment allows fine tuning of cellular functions. Among the most important
processes to precisely control is cell death, as cell death regulators represent the
seeds of a cells demise lurking within at all times. Caspase activation in the
wrong time and place can have disastrous implications for the organism,
considering the feed forward mechanism built into the system. In light of this,
many levels of regulation have been built into the caspase activation process,
including many examples of ubiquitin-proteasome related control. The most
important cell death-related ubiquitin ligases are the IAPs, which, in vertebrates
and Drosophila, are vital regulators of caspases. IAPs are RING domain-
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containing E3s, however, a different class of molecule from dre-1, which is an F
box protein. F box proteins are known to act as E3s through a multi-subunit
complex, the SCF complex. In these complexes, the E2-recruiting RING domain
is supplied by an Rbx1/Roc1-like protein, which binds to a cullin scaffolding
protein. The cullin, in turn, binds to a SKP1-like protein which binds to the F box
protein via the F box domain. The F box protein supplies the specificity of the
SCF E3 ligase, binding via its C-terminus to the substrate and bringing the target
into position for ubiquitin to be conjugated to lysine residues in the polypeptide.
To date, no SCF complexes have been reported as regulators of programmed
cell death in C. elegans.

4.2 Results
Knockdown of dre-1, skr-1 or cul-1 prevent tail-spike cell death

dre-1 contains an F box near the N-terminus, known to bind to Skp1-like
proteins which, along with cullin-like and rbx1-like proteins form an SCF complex
to ubiquitinate target proteins. Several lines of evidence suggested to us that

dre-1 may act in an SCF complex regulate tail-spike cell death. First, in all
organisms harboring a dre-1-like gene, the F box is highly conserved. For
example, comparing C. elegans dre-1 to human FBXO11 with the ClustalW tool,
16/41 residues are identical (39%), 12/41 residues are conserved based on
charge and size (29%) and 7/41 are semi-conserved based on steric size and
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shape (17%), bringing the total identical + conserved + semi-conserved to 35/41
(85%). Second, the strongest allele affecting tail-spike cell death (ns39) is a
substitution in the F box changing a semi-conserved serine to a leucine (a
residue of a different chemical class). This serine is adjacent to a valine which is
conserved in all organisms examined except Nematostella vectensis (sea
anemone). This valine is conserved in human, mouse, rat, Drosophila

melanogaster, Xenopus laevis, Caenorhabditis brenneri, Caenorhabditis
briggsae, Caenorhabditis japonica, Caenorhabditis remanei, Brugia malayi,
zebrafish, Tetraodon nigroviridis (pufferfish), Aedes aegypti, Anopheles gambiae,

Ixodes scapularis (black-legged tick), and Ciona intestinalis (sea squirt). Third,
Fielenbach et al. reported that dre-1 physically interacts with SKR-1 and SKR-2
but not SKR-3, -4, -5, -7, -8, -9, -10, -12, -13, -14, -15, -17, -19, -20 or -21 in a
yeast two-hybrid assay and that RNAi against skr-1, cul-1 and rbx-1/2
recapitulated the dre-1 heterochronic phenotype.
While this is suggestive of dre-1 acting in an SCF complex to regulate tailspike cell death, we wanted to test the hypothesis directly by assessing the role
of individual SCF genes in a reverse genetic manner. To do so, we had to
develop a method for screening a defined set of genes for a role in tail-spike cell
death. Using the RNAi feeding library available in the laboratory, we found that
L4s and gravid young adults carrying an RNAi-sensitizing rrf-3(pk1426) mutation
placed on a lawn of RNAi-expressing E. coli gave the strongest tail-spike cell
death phenotype. Feeding animals ced-4 RNAi in this assay resulted in 20% tail-
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spike cell survival illustrating that the penetrance of RNAi effects in this cell are
incomplete (compare to the 100% survival in ced-4(n1162 animals)), but
significant compared to empty-vector bacteria (0% survival) (Fig. 27). In addition
to ced-4, a second positive control for this assay was dre-1, which gave 10%
survival.
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Fig. 27. Knockdown of ced-4 and dre-1 by feeding RNAi induces a partial
tail-spike cell defect.
L4 and gravid adults of the rrf-3(pk1426); nsIs25 genotype were placed on lawns
of bacteria expressing empty vector, ced-4 RNAi and dre-1 RNAi. L1 progeny
were scored for tail-spike cell survival one and two days later (n>100 for each).
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With this method established, we tested the effect of knocking down skr-1,

-2, -3, -5, -7, -8, -9, -11, -12, -13, -15, -17, -18, -19, -20, rbx-1, rbx-2, cul-1, -4, -5,
and -6. Of these genes, only cul-1 gave a significant phenotype: 9% tail-spike
cell survival (Fig. 28). This result is on par with the level of survival of animals
grown on dre-1 RNAi, in which the tail-spike cell survives in 10% of animals.
None of the skr genes gave a significant cell death phenotype, with skr-1 giving
the largest effect, 2%.
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Fig. 28. Knockdown of cul-1 by feeding RNAi induces a partial tail-spike
cell defect.
L4 and gravid adults of the rrf-3(pk1426); nsIs25 genotype were placed on lawns
of bacteria expressing the indicated RNAi. L1 progeny were scored for tail-spike
cell survival one and two days later (n>100 for each).

81

Given that skr-1 and -2 were reported by Fielenbach et al. to interact with

dre-1 in a yeast two-hybrid assay, and skr-1 RNAi had a very weak effect on tailspike cell death, we tested two genetic alleles of skr-1 for tail-spike cell
phenotypes. A deletion allele, ok1696, of skr-1 is viable as a homozygote with
occasional dpy animals present on the plate. skr-1(ok1696);nsIs25 animals had
0% tail-spike cell survival, suggesting that either (1) skr-1 plays no role in tailspike cell death, (2) skr-2 or another gene is redundant and takes over in its
absence, or (3) this allele is not a true null for skr-1. Several lines of evidence
suggest that the correct explanation is the third. First, injection of skr-1 RNAi into
hermaphrodite gonads produces embryonic lethality of most progeny due to
hyperplasia during development (Yamanaka A et al., 2002; Nayak S et al., 2002),
suggesting that the true phenotype of skr-1(null) is embryonic lethality and that
the fully viable ok1696 allele is not a null. Second, another deletion allele which
we have not yet obtained, tm2391, is reported to be inviable as a homozygote
and fails to complement the skr-1(sm151) point mutant (Killian DJ et al., 2008).
Third, the skr-1(sm151) mutation, a weak semidominant allele that is viable,
gives 4% tail-spike cell survival, compared to 0% for nsIs25 alone (Fig. 29). This
result shows that skr-1 (and possibly its close relative skr-2) is required for tailspike cell death.
A cul-1 allele (e1756) exists that has a sterile phenotype as a homozygote:

cul-1 is maternally provided from a heterozygous mother to her homozygous
progeny, who display a lon phenotype and whose progeny are embryonic lethal
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due to lack of cul-1. Because of this lethality phenotype, we were only able to
score sterile animals, and of these, 0% had a surviving tail-spike cell (Fig. 29).
With these limitations, we are unable to test genetically cul-1s role in tail-spike
cell death, but given the RNAi phenotype, and that Fielenbach et al. also
described a cul-1 RNAi phenotype for dre-1-related processes, we conclude that

dre-1 acts in an SCF complex made up of dre-1, skr-1, cul-1 (and presumably
rbx-1 and/or -2) to regulate tail-spike cell death.
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Fig. 29. The skr-1(sm151) weak loss-of-function allele weakly blocks tailspike cell death.
Percent of animals with a surviving tail-spike cell in strains with the indicated
genotypes (n>100 for each). All strains contain the nsIs25 transgene to mark the
tail-spike cell.
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Abida et al. reported that dre-1s human homolog, FBXO11, has the
capability to neddylate proteins (Abida et al., 2007). We tested whether RNAi
against the C. elegans nedd (ned-8) affected tail-spike cell death. 0% of animals
grown on ned-8 RNAi had surviving tail-spike cells, and we conclude that ned-8
is not required for tail-spike cell death (Fig. 28).

DRE-1 physically interacts with SKR-1 via the F box
These genetic data suggest a model in which DRE-1 binds to SKR-1 (and
possibly SKR-2) which binds to CUL-1 and the remainder of the SCF complex to
regulate tail-spike cell death. As in other DRE-1-like proteins and their
interactions with SKP-like proteins, the DRE-1-SKR-1 interaction should require
an intact F box domain but not CASH domains. To test this hypothesis, I
performed immunoprecipitation experiments with myc- and HA-tagged forms of
these proteins expressed in Drosophila Schneider S2 cells (Fig. 29).
Immunoprecipitation with anti-HA-agarose beads successfully enriched for HAtagged DRE-1, DRE-1(ns39), DRE-1(dh99). Western blot analysis for myctagged SKR-1 showed that HA::DRE-1 and HA::DRE-1(dh99) but not HA::DRE1(ns39) or myc::SKR-1 alone immunoprecipitated myc::SKR-1. That both the
HA::DRE-1 and HA::DRE-1(dh99) proteins bound myc::SKR-1 but not HA::DRE1(ns39) are consistent with the F box being required for DRE-1-SKR-1 binding
and gives biochemical logic to the genetic phenotypes of the dre-1(ns39) and

dre-1(dh99) mutants.
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SKR-1

anti-myc immunoblot
Lane 1:
Lane 2:
Lane 3:
Lane 4:
Lane 5:
Lane 6:
Lane 7:
Lane 8:

myc::SKR-1
myc::SKR-1
myc::SKR-1
myc::SKR-1
myc::SKR-1
myc::SKR-1
myc::SKR-1
myc::SKR-1

+
+
+
+
+
+
+
+

0, input
HA::DRE-1, input
HA::DRE-1(ns39), input
HA::DRE-1(dh99), input
0, IP anti-HA
HA::DRE-1, IP anti-HA
HA::DRE-1(ns39), IP anti-HA
HA::DRE-1(dh99), IP anti-HA

Fig. 30. DRE-1 binds to SKR-1 and the ns39 F box mutation inhibits this
interaction.
myc::SKR-1 was expressed alone or in the presence of wild-type HA::DRE-1,
HA::DRE-1 with the F box mutation (ns39), or HA::DRE-1 with the CASH domain
mutation (dh99). Immunoprecipitation was performed using anti-HA beads to
enrich for HA::DRE-1 proteins, and immunoblotting was performed with anti-myc
antibodies to detect myc::SKR-1. The F box mutation affects SKR-1 binding to
DRE-1, but the C-terminal CASH domain mutation does not.

NB: I plan to replace this blot with one that is better exposed in the coming
weeks.
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4.3 Conclusions
Our results show that DRE-1, in concert with SKR-1, CUL-1, and, most
likely, RBX-1/2 form an SCF complex to regulate tail-spike cell death. Via either
RNAi knockdown or genetic alleles we were able to observe tail-spike cell effects
of loss of dre-1, skr-1 and cul-1. In addition, our biochemical studies suggest that
the interaction of DRE-1 with SKR-1 is mediated by the F box, and that the dre-

1(ns39) missense mutation affects this binding, while the dre-1(dh99) mutation
does not. These results are in line with earlier expression experiments which
suggested that skr-1 and cul-1 are ubiquitous proteins, expressed during
embryogenesis. While these data show that the dre-1 SCF complex is an
important regulator of tail-spike cell death, and establish this E3 ligase as the first
to our knowledge to be involved with programmed cell death in C. elegans.
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Chapter 5: DRE-1/FBXO11 is mutated or deleted in human
lymphomas and may interact with CED-9/BCL2 to induce its
degradation

5.1 Background
Evasion of apoptosis is a requirement of every cancer cell, as the
accumulation of genotoxic stress, hypoxia, lack of growth factors and other
insults should lead to the apoptotic removal of nascent tumor cells (Hanahan and
Weinberg, 2000). However, as evidenced by the high rate of p53 mutations in
almost all cancers (greater than 50%), as well as the incidence of BCL2
amplifications and translocations, these pro-death signals can be evaded through
mutation. Indeed, BCL2 was first described as a translocation partner with the
immunoglobulin heavy chain locus in the t(14;18) translocation found in follicular
lymphoma. Further studies showed that BCL2 is dysregulated in many B cell
lymphoma subtypes, including diffuse large B cell lymphoma, by translocation,
genomic amplification and transcriptional upregulation (Lenz and Staudt, 2010).
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Pro-apoptotic genes, such as p53, on the other hand, are frequently deleted or
mutated to produce loss-of-function phenotypes, preventing apoptosis from
proceeding. Because of the conserved nature of dre-1 across metazoans, the
central importance of ced-9 as the only known anti-apoptotic gene in C. elegans,
the epistasis results suggesting that dre-1 acts upstream of or in parallel to ced-

9, and the frequency of BCL2 dysregulation in human lymphoma, we investigated
whether FBXO11 acts as a tumor suppressor in human lymphoma and whether
DRE-1/FBXO11 regulates CED-9/BCL2 turnover.

5.2 Results
DRE-1 and CED-9 interact with low affinity in Drosophila S2 cells
To test whether DRE-1 and CED-9 interact physically, we expressed
HA::DRE-1 in the presence or absence of myc::CED-9 in Drosophila S2 cells and
used magnetic beads to immunoprecipitate myc::CED-9 and anti-HA
immunoblotting to detect HA::DRE-1 in the lysates (Fig. 31). We observed a
consistent increase in HA::DRE-1 detected in the lysates when myc::CED-9 was
present compared with when myc::CED-9 was absent. However, HA::DRE-1
was also consistently weakly immunoprecipitated with anti-myc beads in the
absence of myc::CED-9, and this non-specific interaction could not be eliminated
by altering the wash buffer conditions as more stringent washes eliminated the
specific interaction as well. Therefore, we are able to detect an interaction, albeit
a weak one, between DRE-1 and CED-9 in vitro.
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1

2

3

4

Anti-HA immunoblot.
Lane 1: HA::DRE-1 + 0, input
Lane 2: HA::DRE-1 + 0, IP anti-myc
Lane 3: HA::DRE-1 + myc::CED-9, input
Lane 4: HA::DRE-1 + myc::CED-9, IP anti-myc
Fig. 31. DRE-1 and CED-9 interact with low affinity in Drosophila S2 cells.
HA::DRE-1 was expressed alone (lanes 1 and 2) or together with myc::CED-9
(lanes 3 and 4). Immunoprecipitations were performed with anti-myc antibodies
and immunoblotting with anti-HA antibodies to detect HA::DRE-1. While some
non-specific binding is present in lane 2, a specific interaction is apparent in lane
4.

We also attempted to visualize CED-9 protein in the tail-spike cell, as one
prediction from our model is that, in dre-1(ns39) mutants, CED-9 should
accumulate due to a lack of dre-1 SCF activity. We obtained an anti-CED-9
antibody from Barbara Conradt, and used two fixation and staining protocols to
immunostain ced-3(n2436) and dre-1(ns39);ced-3(n2436) animals. We chose
these strains as the ced-3 mutation would allow visualization of the tail-spike cell
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in L1 animals in dre-1(wild-type) animals; otherwise, the cell would have died in
embryogenesis. Despite successful staining with another, unrelated antibody in
these experiments (anti-AJM-1), we were unable to observe CED-9 staining in
either strain. This could be due to faulty staining with the anti-CED-9 antibody, to
CED-9 levels being at a level below detection even in dre-1(ns39) animals, or to
the dre-1(ns39) mutation not having an effect on CED-9 protein levels.

FBXO11 is mutated or deleted in human lymphoma and these mutations
cause reduced function

dre-1 is one of the few F box proteins which is conserved across metazoans, with
82% similarity to human FBXO11. Given this remarkable similarity, we wondered
whether it plays a role in apoptosis in other organisms, and specifically whether it
could function as a tumor suppressor in human cancer. In a serendipitous
connection, I suggested this possibility to Dr. Louis Staudt at NCI, who noticed
that certain lymphoma cell lines have deletions or mutations that affect the
FBXO11 locus. The Farage cell line contains a double deletion that removes
FBXO11, the MedB1 line has a single deletion, and OCI-Ly1 contains a
missense mutation as well as a nonsense mutation. His group also identified
mutations in FBXO11 when sequencing DNA derived from primary diffuse large
B-cell lymphoma (DLBCL) tumor samples. Four mutations were found in
germinal center-like DLBCL (GCB-DLBCL), representing 5% of tumors
sequenced and two mutations were found in activated B-cell-like DLBCL (ABC-
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DLBCL). These mutations, with the mouse ENU-derived mutation (Jeff) and the

C. elegans mutations, are a mixture of missense mutations and nonsense
mutations, and are summarized below (Fig. 32).

Fig. 32. dre-1 and FBXO11 mutations from C. elegans mutants and patient
samples.
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We wondered whether these mutations would affect dre-1 function in the
tail-spike cell. To address this question, we expressed mutant forms of the dre-1
cDNA in the tail-spike cell using the aff-1 promoter and assessed their ability to
rescue the dre-1(ns39) phenotype. The Y560C mutation found in a lymphoma
cell line susceptible to FBXO11 expression (see below), corresponds to the
Y2218C mutation in C. elegans. When modeled in the tail-spike cell, this mutant
retained some rescue ability, but was less efficient at killing the tail-spike cell than
the wild-type cDNA, resulting in 39, 41 and 45% tail-spike cell survival in three
independent lines (Fig. 33). The human nonsense mutation at position 256 was
even less effective at rescuing tail-spike cell death, with the cell surviving 65% of
the time. These results show that the human mutations produce a hypomorphic
protein, which is consistent with other loss-of-function mutations in tumor
suppressor genes.
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Fig. 33. Mutated forms of DRE-1/FBXO11 found in lymphomas have
reduced ability to rescue the dre-1(ns39) tail-spike cell death defect.
DRE-1(2218) corresponds to the Y560C mutation in FBXO11; DRE-1(1960)
corresponds to the 256Stop mutation in FBXO11. All cDNAs were expressed
using the aff-1 promoter. Rescue of the dre-1(ns39) defect with the wild-type
cDNA (aff-1p::DRE-1) is included for comparison. n>100 for each.
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Overexpression of FBXO11 in human lymphoma lines induces apoptosis
Given the role of dre-1 in apoptosis and the discovery of possible loss-offunction mutations in human lymphomas, it is possible that FBXO11 is a proapoptotic gene in human cells. If so, then its expression might induce death, a
possibility that Lixin Rui, a post-doctoral fellow in Dr. Staudts lab, investigated
(all experiments described below involving human cells were performed by Dr.
Rui). Transduction of a panel of lymphoma cell lines with a retrovirus expressing
FBXO11 and GFP allowed the toxicity of FBXO11 to be evaluated via flow
cytometry. While 11/18 lines showed no effect on viability over 8 days posttransduction, 7/18 exhibited a clear cell death phenotype (Fig. 34). Importantly,
the three lines with deletions or mutations in FBXO11 – MedB1, Farage and OCILy1 – showed a marked decrease in viability after FBXO11 expression,
suggesting that loss of FBXO11 made these lines especially vulnerable to
reintroduction of FBXO11.
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Fig. 34. Induction of FBXO11 expression kills certain lymphoma cell lines.
Various DLBCL cell lines and two Hodgkin lymphoma cell lines, as indicated,
were transduced with FBXO11 retrovirus. FBXO11-expressing cells were
monitored by flow cytometry for a co-expressed GFP marker. The percentage of
live GFP-positive cells for each time point was normalized to day 0. Lixin Rui and
Lou Staudt, unpublished data.
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This cell death phenotype was accompanied by hallmarks of apoptosis.
Farage and MedB1, two of the lines most susceptible to FBXO11-induced death,
showed an increase in cleaved PARP as well as active caspase-3 as assayed by
flow cytometry (Fig. 35). VP16 expression was used as a positive control for
induction of apoptosis.
FBXO11 induction did not affect the cell cycle in either cell line (Fig. 36).
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Fig. 35. FBXO11 expression induces apoptosis in lymphoma cell lines.
Analysis of apoptosis with active caspase-3 and cleaved PARP in Farage and
MedB1 cells expressing FBXO11 for the indicated times. Positive control cells
were treated with VP16 as indicated times and concentrations. Lixin Rui and Lou
Staudt, unpublished data.

Fig. 36. FBXO11 expression does not affect the cell cycle.
Flow cytometric analysis of the cell cycle in Farage and MedB1 cells induced for
the expression of the FBXO11 for the indicated days. Empty vector served as a
control. Lixin Rui and Lou Staudt, unpublished data.
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FBXO11 kills lymphoma cells via degradation of BCL2
Because of the apparent connection between dre-1 and ced-9 in C.

elegans, Dr. Rui tested whether induction of FBXO11 expression in Farage cells
affected BCL2 levels. Remarkably, BCL2 levels decreased over the course of 4
days of FBXO11 expression, while no such change occurred in empty vector
transduced cells (Fig. 37). This reduction in BCL2 protein level was evident both
via immunoblot and flow cytometry.

Fig. 37. BCL2 protein levels fall after FBXO11 expression.
(A) Immunobloting analysis of BCL2 levels after FBXO11 induction in Farage
cells. The cells were transduced with FBXO11 or empty vector virus with
puromycin selection marker and then induced for the expression of the FBXO11
for the indicated days.
(B) Flow cytometric analysis of the levels of BCL2 in the cells treated as in A.
Lixin Rui and Lou Staudt, unpublished data.
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Cell killing was significantly reduced when using mutant forms of FBXO11
derived from patient samples, the mouse mutant, and C. elegans mutants (Fig.
38). Furthermore, the potency of killing was well-correlated with the level of
reduction of BCL2 protein detected by flow cytometry.

A

B

Fig. 38. The ability of FBXO11 to kill lymphoma cells and affect BCL2
levels is diminished in mutant forms of the protein.
(A) Farage cells were transduced with various mutant FBXO11 viruses and then
expression was induced for 6 days. Shown is flow cytometric analysis of the
levels of BCL2 protein.
(B) Farage cells were transduced with various FBXO11 retrovirus as indicated.
FBXO11-expressing cells were monitored by flow cytometry for a co-expressed
GFP marker. The percentage of live GFP-positive cells for each time point was
normalized to day 0.
FBXO11 mutations: Y560C from OCI-Ly1 GCB cell line, T241A and stop256 (Nterminal 256 aa) from GCB patient samples. S244L from mouse ENU
mutagenesis model. C99L, G420S and stop730 from C. elegans mutations. Cterminus (deletion of F-BOX domain) as a control. Lixin Rui and Lou Staudt,
unpublished data.
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To test whether overexpression of BCL2 could rescue the toxicity of
FBXO11, HA-BCL2 was transduced into Farage cells and single cell clones
expressing GFP and BCL2, or GFP and empty vector were selected. Those
clones that expressed low levels of BCL2 (#9 and 10, as well as empty vector),
but not those that expressed higher levels of BCL2 (#13, 15, 3, 11) were killed by
FBXO11 induction (Fig. 39). Thus, a threshold level of BCL2 expression was
required to rescue FBXO11 toxicity in Farage cells.
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Fig. 39. Overexpression of BCL2 rescues the toxicity of FBXO11 to Farage
cells.
Top panel: HA-BCL2 was transduced in Farage cells and single cell clones were
obtained after hygromycin selection. These single cell clones were individually
infected with FBXO11 retrovirus or empty vector with a GFP marker. Live
FBXO11-expressing, GFP+ cells were monitored by flow cytometry over time
following FBXO11 induction. Data were normalized today 0.
Bottom panel: Flow cytometric analysis of the levels of BCL2 protein in panel A
samples after 6 days induction of FBXO11 compared to day 0. Lixin Rui and Lou
Staudt, unpublished data.
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The Farage line was selected for FBXO11 induction experiments because
it completely lacks endogenous FBXO11 expression and is highly susceptible to
killing upon FBXO11 reintroduction. However, to test whether FBXO11 and
BCL2 interact physically, Dr. Rui used the Riva and OCI-Ly1 lines, which
endogenously express FBXO11 and BCL2 but are also killed upon FBXO11
overexpression. Immunoprecipitation of lysates from Riva and OCI-Ly1 with an
FBXO11 antibody but not a control antibody led to detection of BCL2 via
immunoblotting (Fig. 40). Immunoprecipitation with the FBXO11 antibody from
Farage serves as a negative control, since it expresses no FBXO11 but a large
amount of BCL2.

Fig. 40. FBXO11 and BCL2 interact in Riva and OCI-Ly1 cell lines.
Immunoprecipitation with FBXO11 antibody but not a control antibody reveals an
interaction between FBXO11 and BCL2. FBXO11 band is indicated by arrow.
Lixin Rui and Lou Staudt, unpublished data.
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The proteasome inhibitor PS-341 was used to test whether reduction of
proteasome function would affect BCL2 immunoprecipitation with FBXO11. In
both Riva and OCI-Ly1, there was an increase in BCL2 immunoprecipitated in
the presence of PS-341, compared to no drug (Fig. 41, top panel). In the Riva
cell line, this increase in BCL2 was evident over the 3 hour time course, as was a
band corresponding to BCL2 in the anti-ubiquitin blot (Fig. 41, middle panel).
The reciprocal experiment, in which BCL2 was immunoprecipitated in the
presence of PS-341 and the lysate probed for FBXO11 showed a similar modest
increase in FBXO11 over the 3 hour time course (Fig. 41, bottom panel). These
results suggest that FBXO11 and BCL2 interact in these cell lines and their
interaction is enhanced in the presence of the proteasome inhibitor PS-341.
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Fig. 41. Proteasome inhibition enhances BCL2 immunoprecipitation by
FBXO11.
Cell lines were treated with PS-341 proteasome inhibitor for the indicated times
and immunoprecipitated with antibodies against either FBXO11 or BCL2 and
immunoblotted for the other. Lixin Rui and Lou Staudt, unpublished data.
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5.3 Conclusions
Our results, in collaboration with Lou Staudt and Lixin Rui, suggest that
FBXO11 is mutated in human lymphoma, and these mutations are loss-offunction mutations, both in the context of human cells and the tail-spike cell.
Also, reintroduction of FBXO11 into human lymphoma cell lines that have lost the
gene leads to their apoptotic death, and BCL2 overexpression can rescue this
cell killing. FBXO11 interacts with BCL2 in lymphoma cells and leads to its
degradation. Finally, we present evidence suggesting that DRE-1 and CED-9
physically interact in vitro, though we are unable to detect CED-9 protein in the
tail-spike cell of dre-1(ns39) mutants by immunofluorescence.
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Chapter 6: Characterization of global ced-3 transcription and a
mutant that affects ced-3 transcription in the tail-spike cell

6.1 Background
Tail-spike cell death is unique in several ways, including the fact that it
occurs a long time after the cell is born. Maurer et al. showed that a ced-

3pro::gfp transcriptional reporter is activated just before the cell dies, suggesting
that ced-3 transcription is the trigger for the cell to die (Maurer et al., 2007).
Furthermore, deletion of three small, conserved regions within the promoter
abolished ced-3pro::gfp expression, showing that transcription factors must bind
to the promoter to activate transcription. A forward genetic screen for mutants in
which the ced-3pro::gfp construct fails to be activated identified three
independent mutants, ns114, ns115 and ns90. ns114 and ns115 mapped to the

pal-1 gene, a homeodomain transcription factor important in many cell fate
decisions during development. Electrophoretic mobility shift assays showed that
PAL-1 binds to the ced-3 promoter to control tail-spike cell death, and the pal-
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1(ns114) and ns115 loss-of-function alleles block tail-spike cell death. These
results established the importance of ced-3 transcription in control of tail-spike
cell death, but little was known about ced-3 transcription in other cells. In
addition, the ns90 mutation, which completely blocks ced-3 transcription in the
tail-spike cell, remained uncloned. We set out to address these two issues.

6.2 Results

ced-3 is transcribed in most cells during development, including many that
do not undergo programmed cell death
To create a transcriptional reporter that would include all relevant promoter
sequences, we used the pJ40 plasmid, which has been shown to rescue the cell
death defect of ced-3 mutants (Yuan et al., 1993). Into this plasmid, which
contains 7.6 kb of ced-3 genomic DNA, we inserted the GFP sequence, followed
by a stop codon. Thus, this construct encodes a protein containing the first 69
amino acids of CED-3 fused to GFP, followed by a long 3'UTR that includes the
remainder of the ced-3 gene and its own 3'UTR. Because such complicated
mRNAs may be degraded by nonsense-mediated decay, we injected this
construct into smg-1(r861) animals, which have been reported to allow
expression of such transgenes (Wilkinson et al., 1994).
This reporter turned on ~100-150 minutes post-fertilization and expressed
in most cells until the end of the comma stage of embryogenesis (Fig. 42). At
this time, GFP was expressed in fewer and fewer cells, until hatching when GFP
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was only reliably expressed in the tail-spike cell and occasionally in cells in the
head (Fig. 42c). In addition, ced-3 was also expressed in the male tail in L4
animals (Fig. 42d).
Having established that ced-3 is transcribed in the tail-spike cell just
before its death, we wondered whether a similar mechanism acted in other dying
cells. To address this, we studied this reporter in smg-1(r861); ced-3(n717)
animals, and found that there was no change in the expression pattern. If ced-3
transcription is upregulated in all doomed cells just before their deaths, we would
expect to see many cells in this strain that turned on the reporter just before their
scheduled death but continued to express GFP after they survived
inappropriately. Instead, we saw no evidence of these surviving, GFPexpressing cells, including in larvae in which cells die post-embryonically.
Instead, we saw no significant GFP expression in larvae outside the tail-spike cell
(Fig. 42e). We conclude that ced-3 is transcribed in 100-150 minute embryos,
and this mRNA or protein is inherited during development, when it can become
activated in cells destined to die.
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Fig. 42. ced-3 is transcribed in many cells during developmental periods of
cell death.
Top and bottom panels for each image are DIC+fluorescence and fluorescencealone images, respectively. (A) Image of a smg-1(r861) embryo expressing a
transgene consisting of the full rescuing (7.6 kb) ced-3 genomic locus, into which
GFP with a nuclear localization signal near the start codon was inserted. (B)
Same as A. Notice cell corpse (circled) weakly expressing GFP. (C) A smg1(r861) larva containing the same transgene as in A. Notice the absence of GFP
expression. The observed fluorescence is caused by autofluorescence from gut
granules. (D) A smg-1(r861) L4 male larva containing the same transgene as in
A. Notice the bright expression in several cells in the tail. None of these cells is
fated to die. (E) A smg-1(r861); ced-3(n717) larva containing the same
transgene as in A. Notice the GFP expression in the tail-spike cell (arrows).
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ns90 blocks ced-3 transcription and apoptosis in the tail-spike cell
The ns90 mutation was isolated from a screen for regulators of ced-3
transcription in the tail-spike cell. ced-3(n717); ced-3pro::gfp animals, in which
the tail-spike cell survives inappropriately in 100% of animals and expresses
GFP, were mutagenized and F2 progeny in which ced-3pro::gfp was no longer
present were sought. Three mutants were isolated from this screen, ns114,

ns115 and ns90. ns114 and ns115 were shown to be partial loss-of-function
alleles of pal-1, in which the block in ced-3 expression in the tail-spike cell was
incomplete. ns90, on the other hand, produces a complete block in tail-spike cell

ced-3 transcription, such that the nsIs25 transgene is off in 100% of animals. In
addition, ns90 is a semi-dominant mutant, as 96% of heterozygotes also lack

ced-3 transcription in the tail-spike cell.
Because of the complete block in ced-3pro::gfp expression in ns90
mutants, we are unable to assess whether the mutation has an effect on tailspike cell death or if it is instead never born. To circumvent this issue, we
crossed the ns90 mutation to the ced-5(n1812) background, in which apoptotic
corpses persist inappropriately, allowing us to determine whether the cell has
died. In ns90; ced-5(n1812) animals, a corpse is present in 41% of animals and
absent in 59% (Fig. 43). These data suggest that the tail-spike cell is born and
dies in less than half of animals, and in the remainder it is born and survives
inappropriately, even though we are unable to visualize it with the ced-3pro::gfp
reporter.
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Fig. 43. The ns90 mutation blocks tail-spike cell death in addition to ced-3
transcription in the tail-spike cell.
Left: The tail of a ced-5(n1812) engulfment defective L1 larva in which the round,
button-like tail-spike cell corpse is evident in DIC and fluorescence.
Right: The tail of an ns90; ced-5(n1812) larva in which no corpse is evident. 59%
of animals of this genotype fail to display a corpse, suggesting that the ns90
blocks tail-spike cell death in 59% of animals. All animals contain the nsIs25
transgene as a marker for ced-3 transcription in the tail-spike cell. n=30.
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Because the ns90 mutation appears to not only affect ced-3 transcription
but also tail-spike cell death, we set out to map this mutant via standard SNPmapping techniques. However, because of the allele's dominance, we were
forced to map the mutation based on the absence of the phenotype, i.e., picking
recombinants in which the phenotype and mutation were lost. We were able to
map the mutation to a 0.25 MU interval on Chromosome II between T05C12.9
(0.75 MU) and nfi-1 (0.5 MU). We sequenced several genes in this interval,
including lir-1, lir-2 and lin-26, and identified a mutation in lin-26. This mutation, a
G to A change in the first zinc finger of the protein, is predicted to substitute an
isoleucine for a methionine. Because of the difficulty of rescuing dominant
mutations, we attempted to induce the ns90 phenotype in wild-type animals by
expressing the mutated form of lin-26 in the tail-spike cell. This strategy proved
unsuccessful, as 100% of ced-3; nsIs25 animals carrying this transgene retained

ced-3pro::gfp expression (n=30). Thus, we are unable to determine whether the
mutation in lin-26 is responsible for the ns90 phenotype.

6.3 Conclusions
We have shown that the ced-3 caspase is expressed in most cells during
embryogenesis, including cells that do not undergo programmed cell death. This
result is consistent with previous work showing that cells that do not undergo
programmed cell death retain the pro-death activity of ced-3, although this killing
activity is kept in check (Shaham and Horvitz, 1996b). Thus, it appears that ced-
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3 is transcribed relatively early in embryogenesis, and either the transcript or
protein is inherited during cell divisions until it is activated in cells fated for
programmed cell death.
In addition, we showed that the ns90 mutation, which was known to block

ced-3 transcription in the tail-spike cell, also prevents tail-spike cell death. We
were unable to conclusively identify the gene relevant for the ns90 phenotype,
although we did identify a mutation in lin-26, a zinc-finger transcription factor
(Labouesse et al., 1994). The mutation present in the ns90 strain is a
substitution in the first zinc-finger domain, which could disrupt binding of LIN-26
to the ced-3 promoter. Indeed, while PAL-1 binds to the ced-3 promoter in two
defined domains, the transcription factor(s) that bind to the third domain shown
by Maurer et al. to be important for ced-3 transcription in the tail-spike cell remain
unknown (Maurer et al., 2007). It is possible that LIN-26 is the relevant
transcription factor, and the mutation we identified disrupts the ability to bind to
this site. It is unclear why such a mutation would be dominant and so highly
penetrant, although if LIN-26 acts in a dimer it could bind to and inactivate the
wild-type form of the protein. Regardless, further work is required to elucidate the
molecular basis of the ns90 mutation.
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Chapter 7: Discussion and Future Directions

Programmed cell death is a process crucial to the development of
metazoans, and the genes underpinning this process are functionally important
for development and disease, as well as fundamental to how life works. We have
used the C. elegans tail-spike cell as a model for uncovering genes relevant to
cell death, and these studies have revealed that a conserved F box protein, dre-

1, is required for tail-spike cell death.
dre-1 acts within an SCF complex to regulate death, and represents a new
mode of cell death control that bypasses egl-1 to control caspase activation. dre-

1 requires ced-9 for the majority of its function, suggesting that dre-1 acts
upstream of and/or in parallel to ced-9. Given that SCF complexes are known to
induce ubiquitination and degradation of target proteins, and with our
collaborators' results showing that FBXO11 and BCL2 interact physically, we
favor a model in which the DRE-1 SCF complex inhibits CED-9 function directly,
via ubiquitin-mediated proteolysis (Fig. 44). The ced-9 epistasis results suggest
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this model, but they also suggest that dre-1 may function via another, ced-9independent pathway. This is because in the absence of ced-9 function (i.e., the

ced-9(n2812) null mutation), the tail-spike cell still survives in 20% of animals.
The only caveat to this result is that this strain contains three mutations, dre-

1(ns39), ced-9(n2812) and ced-3(n2427), as well as the tail-spike cell integrated
marker, making it possible that this highly unnatural state produces other effects
that prevent tail-spike cell death (for example, ced-4 expression could be
affected). This result leads us to place dre-1 upstream of ced-9, but also in
parallel to it.
Our model also assumes that rbx-1 and/or -2 are part of the SCF complex
that regulates tail-spike cell death. While we did not observe a tail-spike cell
death phenotype for these genes, they are likely part of this complex, fulfilling the
crucial E2 recruitment role. The lack of a discernable tail-spike cell phenotype in

rbx-1 or -2 RNAi may be due to the difficulty of performing RNAi in the tail-spike
cell: even in the rrf-3 RNAi-sensitized background, knockdown of ced-4, which
we would expect to give 100% survival based on the ced-4(n1162) allele, gives
only 20% survival, illustrating that RNAi by the feeding method has a very weak
effect in the tail-spike cell. Thus it is possible that the RNAi clones directed
against rbx-1 and rbx-2 are unable to sufficiently knockdown the genes' function
in order for us to observe an effect in the already weak tail-spike cell RNAi assay.
Furthermore, feeding RNAi does not allow us to knockdown both genes
simultaneously, so it is likely that knockdown of one gene results in redundant
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compensation by the other. Thus, we are confident that DRE-1 acts in an SCF
complex with SKR-1, CUL-1 and RBX-1/2.
Our model also suggests that DRE-1 acts directly on CED-9 to regulate
cell death. As has been the case with many other E3 ligases, defining the
target(s) of dre-1 has been very difficult. We attempted to demonstrate an
interaction between DRE-1 and CED-9 and found that they interact with weak
affinity in vitro. That this interaction is difficult to detect may be due to the fact
that we lack a C. elegans system in which DRE-1 and CED-9 are endogenously
co-expressed, and instead we must ectopically express these proteins in

Drosophila cells. If modifications are necessary to regulate this interaction, as is
often the case in F box protein/substrate interactions, they may not be occur in
this context. Also, because we lack specific antibodies appropriate for
immunoprecipitation of DRE-1 and CED-9, we must use tagged forms of these
proteins, which may affect their ability to interact. However, our results give
evidence for a weak interaction of CED-9 and DRE-1.
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Fig. 44. A model for dre-1s role in tail-spike cell death.
Our results suggest that dre-1, in concert with its SCF complex partners (not
shown), acts upstream of, or in parallel to ced-9, and may also act independently
of ced-9 to regulate tail-spike cell death.

What future experiments could allow us to identify the target(s) of DRE-1
in an unbiased manner? First, a genetic screen for dominant mutations that
prevent tail-spike cell death could be informative. Indeed, we attempted such a
screen, and isolated one mutant, ns312, but were unable to clone it, as it
appeared to map to two separate loci and was not strongly dominant. However,
a more exhaustive screen of this variety could isolate a dominant-negative form
of an anti-apoptotic regulator, as ced-9(n1950) was isolated from screens for
inappropriate cell survival. A dominant mutant might represent a mutation that
prevents dre-1's target from interacting with the SCF complex and thus from
being ubiquitinated. In that case, the anti-apoptotic activity of the target protein
would persist and prevent the tail-spike cell from dying. The major caveat to this
screen is that such a mutant may not exist: there may not be a mutation that
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prevents binding of this anti-apoptotic protein to the dre-1 SCF complex while
also leaving its anti-apoptotic function intact. Indeed, our failed attempts at
isolating such a mutant provide support to this idea, although our screen was not
exhaustive and further attempts could prove fruitful here.
A related experiment could address whether CED-9 is the relevant target
of DRE-1 in tail-spike cell death. Wild-type and un-ubiquitinatable ced-9 could be
expressed in the tail-spike cell, and assayed for their ability to prevent tail-spike
cell death. If ubiquitin-mediated destruction or inhibition is necessary for tailspike cell death, then the un-ubiquitinatable form would be expected to prevent
death at a higher rate than the wild-type form. This experiment is difficult,
however, for two reasons. First, there are 13 lysines in CED-9, and it is
impossible to know, a priore, which are relevant. It is intriguing, however, that
CED-9, BCL2 and many of their homologues share a terminal lysine residue.
Second, we know that there is at least one form of CED-9 that dominantly
prevents cell death, n1950, through its egl-1-related interaction. While this
interaction plays a minor role in the tail-spike cell, it might complicate the
interpretation of the results. Third and most importantly, the level of expression
of wild-type and mutant forms of CED-9 are crucial determinants in this
experiment. C. elegans transgenics are known to vary significantly in the copy
numbers of the introduced genes. If either the wild-type or mutant forms of CED9 were expressed at a very high level, the amount of tail-spike cell death in the
strain could be affected, as in either case, high expression of an anti-apoptotic
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protein should prevent death. Excess tail-spike cell survival due to high
expression of CED-9 would have to be distinguished from physiologic expression
of a mutant form that accumulates due to lack of proteasome-induced turnover.
A second avenue toward identifying the target of DRE-1 would be to clone
more mutants from the screen that yielded the dre-1(ns39) mutant. Because
many F box protein-substrate interactions require phosphorylation or other
modification for efficient binding, it is likely that there are other genes involved in

dre-1's pro-apoptotic function in the tail-spike cell. Indeed, another mutant, ns40,
fails to complement dre-1 and does not have a global cell death defect,
suggesting that this may be an interesting mutant. Also, the screen that isolated

ns39 and ns40 is not saturated, so more interesting mutants may be available
after further screening.
Third, DRE-1 binding partners could be isolated with a biochemical
screen. For example, a tagged form of DRE-1 could be used to rescue the tailspike cell death defect and then an antibody against the tag could be used to
isolate DRE-1 and proteins bound to it. Knowing that the tagged form rescued
the death defect would assure that full dre-1 activity was present in the
ectopically-expressed strain. The protein isolation would ideally be done in
embryos, when dre-1 acts in the tail-spike cell; otherwise, dre-1 targets relevant
to heterochronic or early development phenotypes might be isolated instead. Not
only is this a difficult experiment because of the inherent difficulty in performing a
biochemical screen, but also because the tail-spike cell is one of ~1000 cells in
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the animal, and thus the relevant interaction might be below the level of
detection.
Finally, to investigate further whether CED-9 is the target of DRE-1,
biochemical isolation of CED-9 protein from C. elegans embryos followed by
biochemical analysis could be done. If CED-9 is polyubiquitinated,
phosphorylated, or otherwise modified, these modifications might be discernible
by mass spectrometry. While this may be less successful in whole C. elegans
embryos, as the tail-spike cell is one of many cells, it might be more successful in
human lymphoma cells susceptible to FBXO11-induced killing. Identification of
the residues relevant for ubiquitination or other modification would allow those
amino acids to be specifically targeted for mutagenesis in further studies.
While we have focused on the cell death-related target(s) of DRE-1, it
would also be interesting to understand what are the other DRE-1 targets that
govern other developmental processes. For example, dre-1(null) mutants die
during embryogenesis due to severe patterning defects that are unrelated to cell
death. In addition, Fielenbach et al. described a role for dre-1 in heterochronic
phenotypes in larvae (Fielenbach et al., 2007). While these functions are clearly
separable from dre-1's cell death function (that the ns39 mutant is viable but has
a strong tail-spike cell death defect demonstrates this), they may be in some way
shed light on the apoptotic role. A relatively simple screen would be for
suppressors of the lethality of a dre-1(null) mutation.
We showed that most aff-1 mutant animals have a forked tail as L1s, and
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this defect is likely to be due to tail-spike cell non-fusion because fusion of hyp10,
the cell that makes up the tail tip, is governed by eff-1. We have not, however,
formally proved this, as it is possible that the aff-1 mutation affects tail-tip
morphogenesis via another cell, despite the fact that aff-1 is expressed in the tailspike cell but not hyp10. To formally prove that tail-spike cell fusion must occur
for proper tail-tip morphogenesis, we would have to rescue the aff-1 mutation in
the tail-spike cell only. However, no promoter is known that expresses
specifically in the tail-spike cell at an early stage in development.
Our results also suggest that the tail-spike cell process is vital for hyp10
morphogenesis, and when the cell does not fuse, two processes are produced
which direct formation of a forked tail, instead of a normal one. To more directly
address this hypothesis, we could ablate either the developing tail-spike cell soon
after its birth, or the process as it has just begun to form. We would expect that
in either case, hyp10 would be unable to properly form a tail-tip, a defect that
might manifest itself as a blunted tail. The difficulty with this experiment is that
ablations would have to be performed in 3-fold embryos in which the animals are
able to roll within the eggshell. Thus, it would be difficult to ablate such a small
cell, or, better, its even smaller process, in a moving target.

When we recognized that dre-1 is a conserved apoptotic regulator, we
wondered whether its cell death role was conserved, and whether it might act as
a tumor suppressor in human cancer. Our collaborators at the National Cancer
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Institute, Lou Staudt and Lixin Rui, identified human lymphoma cell lines and
patient samples with deletions and mutations in the FBXO11 gene consistent
with the idea that FBXO11 controls apoptosis in human lymphoma (that tail-spike
cell death is governed by two suppressors of human cancer, pal-1/Cdx2 and dre-

1/FBXO11, is truly remarkable). They went on to show that FBXO11 expression
in the cells that had deleted it caused their death, suggesting that, because of the
genetic wiring of these particular cell lines, FBXO11 is especially toxic. In
addition, they were able to show that FBXO11 and BCL2 interact in the cells in
which both are endogenously expressed, and that BCL2 levels fall upon FBXO11
expression.
An ENU-induced mutant in FBXO11 has been described, the so-called
Jeff mouse, which is likely a hypomorphic mutation that leads to perinatal lethality
in homozygotes. Because these mice do not survive beyond a few hours after
birth, we cannot test whether they are cancer-prone. However, as heterozygotes
these animals are viable and show only an inner ear defect. To address whether
FBXO11 plays a role in tumor suppression in mice, these heterozygotes could be
monitored for spontaneous tumor development, although the Jf/+ reduction of
function may not be a strong enough FBXO11 defect to induce tumor formation.
In that case, Jf/+ heterozygotes could be crossed to one of many tumor-prone
mouse models, such as the Eμ-myc model. In these mice, the myc oncogene is
driven by the immunoglobulin heavy chain enhancer, and nearly all mice
containing this transgene develop lymphomas at a young age. If FBXO11 is
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involved in B cell death, Jf/+ Eμ-myc mice might develop tumors at an earlier
age, or their tumors might be more virulent
Another interesting experiment would be to conditionally inactivate
FBXO11 in B cells, replacing the coding sequence in B cells with GFP via the
Cre-lox or other related system. This would allow monitoring of B cell
development in the absence of FBXO11, which might elucidate the step at which
the gene is acting. Simultaneously, it would give information about when during
B cell development FBXO11 is normally expressed. Because B cells may
undergo apoptosis at many steps during their maturation, from early stages when
they must successfully rearrange their immunoglobulin loci to form a competent B
cell receptor, to later stages when they may be deleted based on the affinity of
their receptor for self- and non-self-antigen. We would predict, based on the
mutations found in DLBCL, that FBXO11 is more likely to act in later B cell
development, as these tumors express gene signatures seen in later stage B
cells. A detailed examination of FBXO11 expression in normal B cells with an
anti-FBXO11 antibody would further our understanding of its role in B cell
development.
A related experiment that would help to understand the role of FBXO11 in
vertebrate systems would be the creation of a GFP knock-in mouse to replace
the FBXO11 locus in all cells. This would allow the FBXO11 expression pattern
to be studied in detail during development, along with the null phenotype. We do
not know how far these mice would develop, but if they survived long enough in
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embryogenesis, we would learn in which tissues FBXO11 is expressed with more
accuracy than has been reported via immunostaining.
The Jf/Jf mouse has been reported to possess craniofacial abnormalities
and cleft palate, and shows reduced staining of cleaved caspase-3 in the
developing palate (Tateossian et al., 2009). Intriguingly, Apaf-1 mutants were
also reported with facial deformities and cleft palate (Cecconi et al., 1998). While
there are many mouse mutants with these phenotypes, it is tempting to think that
both the FBXO11 and Apaf-1 defects are cell death-related defects. To address
this question, it would be informative to stain the developing palates of Jf/Jf mice
for Apaf-1 and BCL2, as well as Apaf-1(null) mice for FBXO11 expression;
perhaps the expression of one depends on the presence of the other. Also,
developing palates of wild-type mice could be stained for these proteins, as they
may be expressed in a subset of cells that must undergo programmed cell death
for a normal palate to be formed.
Finally, because of the connection between FBXO11 and BCL2, and
because BCL2 is expressed in tissues outside B cells and has been implicated in
many other cancers, sequencing of the FBXO11 locus in other tumor types could
be informative. While Rui and Staudt found FBXO11 mutation in 5% of germinal
center-like DLBCLs, it is possible that the gene is mutated in other tumor types at
a higher rate. In addition, Tateossian et al. reported that FBXO11 is expressed in
many tissues of the mouse, including lung, brain, bone marrow and kidney. If the
human FBXO11 expression pattern is similar, then FBXO11 may have a role in
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the development of these tissues and may also have tumor suppressive activity
in these tissues. With the ongoing Cancer Genome Atlas and other deep
sequencing projects in progress, we may learn of FBXO11 mutations in other
cancers.
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Chapter 8: Materials and Methods

Strains
All strains were maintained at 20oC on NGM agar with OP50 bacteria. The wildtype strain was N2 Bristol. The following strains were used:
LGI: mir-71(n4115), mir-2(n4108), lin-28(n719), skr-1(sm151, ok1696)
LGII: aff-1(tm2214), eff-1(hy40), ns90, lin-29(n333), lin-4(e912), rrf-3(pk1426)
LGIII: ced-4(n1162, n ), ced-9(n2812, n1950), pal-1(ns114, ns115), cul-1(e1756)
LGIV: ced-3(n717, n2427, n2436, ns38), ced-5(n1812)
LGV: dre-1(ns39, dh99, dh279, gk857), egl-1(n1084n3082), lin-46(ma164)
LGX: nsIs25

Plasmid construction
For the dre-1 transcriptional reporter, 4 kb of genomic DNA upstream of dre-1
exon 2 was amplified by PCR with SalI and BamHI sites incorporated into the
primers and the resulting amplicon was ligated into pPD95-69. For dre-1 cDNA
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rescue constructs, the dre-1 cDNA was amplified from purified mixed stage C.
elegans cDNA and ligated via TOPO cloning into the pCRII-TOPO vector
(Invitrogen). From this template, the dre-1 cDNA was amplified with primers
including SpeI and SalI sites, and the resulting amplicon ligated into pBluescript.
The dre-1 3'UTR was amplified by PCR from genomic DNA and ligated with SalI
and ApaI sites downstream of the dre-1 cDNA in this plasmid. Finally, various
promoters were amplified from genomic DNA and ligated using NotI and SpeI
sites: 4.4 kb of genomic DNA upstream of the aff-1 ATG was used for aff1p::DRE-1 plasmids; 730 bp of genomic DNA upstream of the dpy-30 ATG was
used for dpy-30p::DRE-1 plasmids. dre-1 mutations were introduced into the
cDNA by PCR. Briefly, two anti-parallel primers containing the desired mutation
were used along with primers complementary to the beginning and end of the
cDNA to produce two PCR products that included the desired mutation. These
products were then used as the template for a third PCR in which primers
complementary to the beginning and end of the cDNA were used. The resulting
amplicon was ligated into the plasmid described above in place of the wild-type
cDNA. This strategy was used to create the aff-1p::DRE-1(2218) and aff1p::DRE-1(1960) mutant forms of the cDNA. Drosophila S2 cell culture
transfections were done with the relevant cDNA cloned into the pAC5.1 vector.
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Transgenic strains
All rescue experiments were performed using 5 ng/ul rescuing plasmid or fosmid
+ 15 ng/ul coelomocyte::dsRed coinjection marker (a gift from Carl Procko) + 80
ng/ul pBluescript. Fluorescent reporters were injected at 25 ng/ul with pRF4 rol-6
plasmid.

Immunostaining with anti-CED-9 antibodies
Immunostaining was attempted as described by Finney and Ruvkun (1990), as
well as with the freeze-crack method of Janet Duerr. Goat anti-CED-9 antibodies
were used at 1:50-1:200 concentrations.

Drosophila S2 cell culture
S2 cells were grown in Shields and Sang M3 insect medium with 10% FBS and
penn-strep at 50 units/ml at 25oC. For transfections, 2 million cells in 2 ml culture
medium were split into 6 well plates, and the following day cells were transfected
with 1 ug plasmid DNA + 8 ul Fugene HD Transfection Reagent (Roche).
Analysis was performed 3 days later.

Immunoprecipitation
2-10 ml transfected cells were pelleted by centrifugation and washed with 1 ml
cold PBS. Cells were lysed in 500 ul NP-40 lysis buffer with 250 mM NaCl for 1
hour at 4oC. myc::CED-9 was immunoprecipitated with rabbit polyclonal anti-myc
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(AbCam) + Dynabeads (Invitrogen) for 30 min at 20oC. The complexes were
isolated and washed according to the manufacturer's directions and analyzed by
SDS-PAGE.

RNA interference
HT1114 E. coli carrying the relevant RNAi plasmid were grown overnight at 37oC
in LB+ampicillin. Bacteria were plated on NGM+IPTG+carbenicillin plates and
incubated at 37oC with the lids askew for 3 hours to dry, followed by upside-down
overnight to grow. The following day, rrf-3(pk1426);nsIs25 young adult
hermaphrodites were placed on the lawn. For the next two days, L1 progeny
were scored for tail-spike cell survival under a compound fluorescence
microscope.
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